

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE LITIGATION

MDL No. 1456

THIS DOCUMENT RELATES TO:

CIVIL ACTION: 01-CV-12257-PBS

ALL ACTIONS

Judge Patti B. Saris

TRACK 1 DEFENDANTS' OBJECTIONS TO PLAINTIFFS' PROPOSED EXHIBITS

In addition to the objections enumerated below, each defendant objects to all documents produced by its co-defendants. Specifically, Defendant AstraZeneca Pharmaceuticals LP (“AstraZeneca”) objects to the following exhibits on the grounds that (1) they were produced by co-defendants and are therefore irrelevant and inadmissible under Fed. R. Evid. 402 and (2) they constitute hearsay and are therefore inadmissible under Fed. R. Evid. 801: 176-373, 375-848, 921-932, 935-937, 939-940, 944-947, 951-952, 976-982. Defendant Johnson & Johnson (“J&J”) objects to the following exhibits on the grounds that (1) they were produced by co-defendants and are therefore irrelevant and inadmissible under Fed. R. Evid. 402 and (2) they constitute hearsay and are therefore inadmissible under Fed. R. Evid. 801: 1-234, 375-816, 843-848, 913-919, 935-940, 944-947, 951-952, 980, 982A-Y. Defendant Bristol Meyers Squibb Co. (“BMS”) objects to the following exhibits on the grounds that (1) they were produced by co-defendants and are therefore irrelevant and inadmissible under Fed. R. Evid. 402 and (2) they constitute hearsay and are therefore inadmissible under Fed. R. Evid. 801: 1-175, 235-373, 375-842, 913-919, 921-932, 938-939, 976-982, 982A-Y. Defendants Schering-Plough Corporation and Warrick Pharmaceuticals Corporation (“SP/W”) object to the following exhibits on the grounds

that (1) they were produced by co-defendants and are therefore irrelevant and inadmissible under Fed. R. Evid. 402 and (2) they constitute hearsay and are therefore inadmissible under Fed. R. Evid. 801: 1-373, 817-848, 913-919, 921-932, 935-938, 940, 944-947, 951-952, 976-979, 981-982, 982A-Y.

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|----------------------|-----------------------------------|
| 1 | | 6/20/03 | Memorandum of Plea Agreement in <i>United States v. AstraZeneca Pharmaceuticals, LP</i> , Criminal Action No. 03-55 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 2 | | | Information filed by the U.S. Attorney in <i>United States v. AstraZeneca Pharmaceuticals, LP</i> , Criminal Action No. 03-55 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 3 | | 6/20/03 | Transcript of the Plea and Sentencing Hearing before Honorable Joseph J. Farnan in <i>United States v. AstraZeneca Pharmaceuticals, LP</i> , Criminal Action No. 03-55 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 4 | BERKMAN 0204-05 | 5/19/03 | Information filed by the U.S. Attorney in <i>United States v. Robert A. Berkman, M.D.</i> , Criminal Action No. 03-45 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 5 | | 7/17/03 | Transcript of the Plea Hearing conducted by Honorable Joseph J. Farnan, Jr. in <i>United States v. Robert A. Berkman, M.D.</i> , Criminal Action No. 03-45 (D. Del.) | Relevance FRE 403 | AstraZeneca |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|----------------------|-------------------------------|
| 6 | | 4/19/04 | Examples of Zoladex labels presented as Exhibits at the Ohio State Licensing Board Hearing for Robert A. Berkman, M.D. | Relevance FRE 403 | AstraZeneca |
| 7 | | 9/18/04 | Information filed by the U.S. Attorney in <i>United States v. Saad Antoun, M.D.</i> , Criminal Action No. 02-13 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 8 | | 9/18/02 | Memorandum of Plea Agreement in <i>United States v. Saad Antoun, M.D.</i> , Criminal Action No. 02-13 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 9 | BERKMAN 0212-21 | 5/16/03 | Memorandum and Plea Agreement in <i>United States v. Robert A. Berkman, M.D.</i> , Criminal Action No. 03-45 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 10 | HOPKINS 0122-25 | 9/18/02 | Superseding Information filed by the U.S. Attorney in <i>United States v. Stanley C. Hopkins, M.D.</i> , Criminal Action No. 02-127 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 11 | | 12/17/02 | Memorandum and Plea Agreement in <i>United States v. Stanley C. Hopkins, M.D.</i> , Criminal Action No. 02-127 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 12 | | 11/6/03 | Transcript of Sentencing Hearing in <i>United States v. Robert A. Berkman, M.D.</i> , Criminal Action No. 03-45 (D. Del.) | Relevance FRE 403 | AstraZeneca |
| 13 | | 2/5/04 | Letter from Judge Joseph J. Farnan, Jr. to the State Medical Board of Ohio | Relevance FRE 403 | AstraZeneca |
| 14 | AZ0237142-163 | 11/3/95 | Memorandum from Market Strategy & Contract Operations and the Zoladex Marketing Team | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|--|-------------------|-----------------------------------|
| 15 | AZ0431807-811 | 10/19/00 | E-mail from Margaret Hammons to George Gerhart III | No objection | |
| 16 | AZ0427821-858 | 3/8/99 | Letter from Jacqueline Connelly to Howard Kaplan | No objection | |
| 17 | AZ0465663-665 | 11/30/01 | E-mail exchange re: Drug Topics Red Book and PDR | No objection | |
| 18 | AZ0449165-167 | 6/26/01 | E-mail from John Freeberry to Rick Bartels | Relevance | AstraZeneca |
| 19 | AZ0021762-765 | 1/23/96 | Internal memorandum from Keith Patterson to Chris Iacono | No objection | |
| 20 | AZ0237142-163 | 11/3/95 | Memorandum from Market Strategy & Contract Operations Zoladex Marketing Team to Chris Iacono | No objection | |
| 21 | AZ0435309-316 | | Document titled "Implementation of Catalog Price Changes" | No objection | |
| 22 | FDB-AWP-16989-996 | 7/2/01 | Fax to First Data Bank from Sandra Bell | Relevance | AstraZeneca |
| 23 | AZ0449541-545 | 5/9/00 | E-mail from John Freeberry to Richard Hedinger | Relevance | AstraZeneca |
| 24 | AZ0435202-212 | 5/15/01 | Fax from Judy Roberts to Carol Flanagan | No objection | |
| 25 | AZ0435213-214 | 5/18/01 | Fax to First Data Bank attaching AstraZeneca Revised Price List | Relevance | AstraZeneca |
| 26 | AZ0445417-424 | 8/22/00 | E-mail from Barnabas Desta to Joan McDevitt | Relevance | AstraZeneca |
| 27 | AZ0080413-417 | 11/3/95 | Memorandum from Market Strategy & Contract Operations to Chris Iacono re: Zoladex Pricing and Volume Discount Strategy | No objection | |
| 28 | AZ0036643 | 4/22/96 | Memorandum from Paula Jordon to Fred Roberts re: Zoladex (goserlin acetate) Projects | No objection | |
| 29 | AZ0036585 | 1/29/96 | Letter from Paula Jordon | No objection | |
| 30 | AZ0465663-665 | 11/30/01 | E-mail from John Freeberry to Mark Boyer | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------|-------------|---|-------------------|-----------------------------------|
| 31 | AZ0473119 | 11/27/02 | E-mail from Janet Rosenberg to Traci Kellam | Relevance | AstraZeneca |
| 32 | AZ0433750-756 | 2/27/02 | E-mail from Monique Loeffert to Debra Ann Ivey | No objection | |
| 33 | AZ0437459-460 | 1/3/99 | E-mail from Barbara Villani to Joseph Mansfield | No objection | |
| 34 | AZ0426708, 0426710-13 | 7/14/97 | E-mail from Kaylor Kowash to Rickards, Arenson and Caswell | No objection | |
| 35 | AZ0037022 | | Handwritten Note | No objection | |
| 36 | AZ0017129 | 7/26/96 | Memorandum from MRP to Zeneca File re: Conversation with Mark Reisenauer 7/19/96 | Hearsay | AstraZeneca |
| 37 | AZ0036510-33 | 6/00/95 | Document titled "Zoladex Reimbursement Hotline Activity Report – June 1, 1995 – June 30, 1995" prepared for Zeneca Pharmaceuticals by State & Federal Associates Inc. | No objection | |
| 38 | AZ0105879-881 | | Letter from Chris Bowman to Members of the "Maricopa Urology Lithotripsy Inc." Group | No objection | |
| 39 | AZ0096359 | | Letter from Chris Bowman to Sheila | No objection | |
| 40 | AZ0464087 | 9/13/00 | E-mail from John Freeberry to Julie-Ann Tracy | No objection | |
| 41 | AZ0445640-641 | 6/29/01 | E-mail from Barnabas Desta to David Meddis | No objection | |
| 42 | AZ0407062-065 | 00/00/02 | Sales Representative Call Notes | Relevance | AstraZeneca |
| 43 | AZ0431262-71 | | AstraZeneca Pharmaceuticals Agreement | No objection | |
| 44 | AZ0237164-69 | 11/20/95 | Internal Memorandum to Chris Iacono from Keith Patterson | No objection | |
| 45 | AZ0024479-81 | 1/19/96 | Internal Memorandum to Chris Iacono from Keith Patterson | No objection | |
| 46 | AZ0011640 | 9/10/96 | September 10, 1996 letter from M. Painter to M. Reisenauer | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|---------------------------------|-----------------------------------|
| 47 | AZ0011635-36 | 4/28/97 | Letter from M. Painter to T. Arenson | No objection | |
| 48 | PXL01258-66 | 8/6/96 | Fax from C. Ware to M. Reisenauer | No objection | |
| 49 | HOWE0052-57 | | Patient Financial History Prepared by Oregon Urology Specialists | Relevance FRE 403 Hearsay | AstraZeneca |
| 50 | HOWE0120 | | Billing Statement to Mr. Howe | Relevance FRE 403 Hearsay | AstraZeneca |
| 51 | HOWE0020-21 | | Medicare Summary Notice | Relevance FRE 403 Hearsay | AstraZeneca |
| 52 | HOWE0010 | | Cancelled Check #3995 for \$118.81 Made Out to Oregon Urology Specialists | Relevance FRE 403 | AstraZeneca |
| 53 | TOWN500-503 | | Patient Financial History Report | Relevance FRE 403 Hearsay | AstraZeneca |
| 54 | TOWN0001-2 | | Cancelled Checks Made Payable to Mr. Townsend's Urologist, Dr. E. Richard Grieco | Relevance FRE 403 | AstraZeneca |
| 55 | TOWN 0056 | | Medicare Summary Notice | Relevance FRE 403 Hearsay | AstraZeneca |
| 56 | AZ0702243-46 | 10/16/04 | Email of Erik Schultz | Relevance | AstraZeneca |
| 57 | AZ 0044059-63 | 10/13/95 | Letter to Mark J. Harberberger from William C. Lucas | Relevance FRE 403 | AstraZeneca |
| 58 | ABT 48686-96 | 12/18/95 | Letter from Mark J. Harberberger to William C. Lucas | Relevance FRE 403 | AstraZeneca |
| 59 | ABT 48560-76 | 9/26/95 | Letter from Mark J. Harberberger at Abbott to Glenn M. Engleman at AstraZeneca | Relevance FRE 403 | AstraZeneca |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|----------------------|-----------------------------------|
| 60 | | 6/4/03 | Corporate Integrity Agreement between AstraZeneca and the Office of Inspector General of the Department of Health & Human Services, signed by AstraZeneca | FRE 403 | AstraZeneca |
| 61 | AZ0491331-43 | 2/10/03 | CMS Account Team Kickoff Meeting | No objection | |
| 62 | AZ0037011 | 4/12/95 | Internal Memorandum from Ruth Beedle re: Zoladex Profitability | No objection | |
| 63 | AZ0037036-48 | 9/5/95 | Internal Memorandum from Tom Chen to Mike Bonney re: Zoladex Sample Inventories | Relevance FRE 403 | AstraZeneca |
| 64 | AZ0010307-09 | 4/6/96 | Memorandum to Keith Patterson from Tom Chen re: TAP Response to Zoladex Case Quantity Discount | No objection | |
| 65 | AZ0036661 | 5/7/96 | Memorandum to Mark Reisenauer, Tom Chen from Paula Jordon re: Payer Education Mailings | No objection | |
| 66 | AZ0577665-71 | 6/24/99 | Cost and Suggested List | No objection | |
| 67 | AZ0431261-71 | 6/24/02 | Email from Nancy Jones to Holle Terkhorn re: Annual Buy Group Zoladex Contract Template | No objection | |
| 68 | AZ0461415-65 | 6/2/00 | Urology Portfolio Strategic Plan – TALT Update | No objection | |
| 69 | AZ0004616-38 | | Zoladex Strategic Summary – 1998-2002 by Keith Patterson | No objection | |
| 70 | AZ0682890-907 | 00/00/03 | Zoladex 2003 EFAR Forecast | No objection | |
| 71 | AZ0689131-37 | 12/22/03 | Email from Kathryn Jones re: Data to Support Additional Payment for Part B Drugs in 2004 | Hearsay | AstraZeneca |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|-------------------|-----------------------------------|
| 72 | AZ0463635-38 | 1/23/02 | Email from John Freeberry to Ena West & Erik Schultz re: Pricing New Specs | No objection | |
| 73 | AZ0464456 | 1/00/02 | Pricing News | No objection | |
| 74 | AZ0707711-34 | | Zoladex Market Pricing | No objection | |
| 75 | AZ0462355-56 | 4/4/00 | Email from Joan McDevitt re: Revised AZ Competitors Report | No objection | |
| 76 | AZ0461108-10 | 10/17/02 | Email from Erik Schultz to John Freeberry re: AWP White | No objection | |
| 77 | AZ0005740-41 | 8/21/96 | Internal Memorandum from Mark Reisenauer to Steve Strand re: Zoladex Pricing Recommendations | No objection | |
| 78 | AZ0013233-35 | 10/24/96 | Internal Memorandum from Mark Reisenauer to Keith Patterson and Steve Strand re: Zoladex Price Increase Recommendation | No objection | |
| 79 | | 11/20/95 | Internal Memorandum from Keith Patterson to Chris Iacono re: Zoladex Pricing Strategy | No objection | |
| 80 | AZ0438395-97 | 1/06/00 | Email to JoAnn Smith from Charles Dadonna | No objection | |
| 81 | AZ0437058-60 | | LHRH Cost Comparison | No objection | |
| 82 | AZ0437062 | | Patient on 4 10.8mg Injections | No objection | |
| 83 | AZ0422502-13 | 4/30/97 | Internal Memorandum from Product Management Team for Zoladex to Oncology Care Representatives & Area Business Specialists re: New Options for Credit Card Payments for Zoladex | No objection | |
| 84 | AZ0422517-18 | 7/28/99 | Corporate or Business Structure Questionnaire | No objection | |
| 85 | AZ0422520 | | History of Zoladex Pricing | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------|-----------------------------------|
| 86 | AZ0422592 | | Comparison of 25 Patients on 3 Month Zoladex Therapy for 1 Year vs. 4 Month Lupron Therapy for 1 Year | No objection | |
| 87 | AZ0422630-39 | 06/00/01 | AstraZeneca Pharmaceuticals LP – Integrated Health Systems – Zoladex (goserelin acetate implant) | No objection | AstraZeneca |
| 88 | AZ0424228 | | Comparison of 116 Patients on 3 Month Zoladex Therapy for 1 Year vs. 4 month Lupron Therapy for 1 Year | No objection | |
| 89 | AZ0431034-65 | 3/4/02 | Email from Nancy Jones to Eugenia Glessner re: Lakes Region General Hospital and St. Mary's Regional Medical Center IHS contracts | No objection | AstraZeneca |
| 90 | AZ0431073 | 1/12/99 | Draft Letter to Physician from Kulda & Heisey re: Zoladex Price Increase | No objection | |
| 91 | AZ0694210-65 | 04/00/03 | Office of Inspector General – Compliance Program Guidance for Pharmaceutical Manufacturers | Relevance | AstraZeneca |
| 92 | PTX01034 | 1/19/95 | Letter to Enid Olayan from Carol Ware | No objection | |
| 93 | PXL05552-602 | 8/20/93 | Letter to Keith Patterson from Carol Ware enclosing report on Zoladex calls | No objection | |
| 94 | PXL05638-991 | 2/23/94 | Letter to Keith Patterson from Carol Ware enclosing report on Zoladex calls | No objection | |
| 95 | PXL06067-594 | 2/23/96 | Letter to Keith Patterson from Carol Ware enclosing report on Zoladex injuries | No objection | |
| 96 | PXL01037 | 1/20/95 | Fax from Carol Ware to Medicare Part B Carrier | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|---|-----------------------------------|
| 97 | AZ0036923-26 | 6/14/96 | Memo to Mike Murray from Carol Ware re: CIGNA Medicare Bulletin | No objection | |
| 98 | AZ0021569-71 | 6/17/96 | Fax to Keith Patterson & Mark Reisenauer from Carol Ware re: Colorado Medicare Part B | No objection | |
| 99 | PXL01803-04 | 2/29/96 | Letter to Carol Ware from Sue Walker | No objection | |
| 100 | PXL03970-76 | 10/14/98 | Total Proposals Pending | No objection | |
| 101 | | | Zoladex Label | Relevance FRE 403 | AstraZeneca |
| 102 | | | Zoladex Labeling | Relevance FRE 403 | AstraZeneca |
| 103 | | 4/18/97 | Handwritten Agreement | Hearsay Authentication Relevance FRE 403 | AstraZeneca |
| 104 | | | Lupron Depot 4-Month (30mg) Advantages | No objection | |
| 105 | | 1/29/96 | Zoladex Cost Comparison | No objection | |
| 106 | | 4/10/98 | Letter to Annual Contract Customer from Kathleen Sailer & Earl Heisey | No objection | |
| 107 | | | Zoladex Annual Contract | No objection | |
| 108 | | | Invoice | Relevance FRE 403 | AstraZeneca |
| 109 | AZ0487753-56 | 2/1/93 | Suggested List Prices and Marketing Policy | No objection | |
| 110 | AZ0427978-85 | 6/2/98 | U.S. Wholesale Druggists Cost and Suggest List Prices | No objection | |
| 111 | AZ0018042-44 | 11/4/96 | Internal Memorandum from Mark Reisenauer to Bob Black & Jim O'Shea re: Zoladex Price Increase Recommendation | No objection | |
| 112 | AZ0096314 | | 1-Month Depot Zoladex | No objection | |
| 113 | AZ0096386-88 | 9/26/95 | Memo to Gary Hansen from Chris Bowman re: NSS- "Purchase Groups" | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------|-----------------------------------|
| 114 | AZ0096255-59 | 8/29/97 | Email from Christopher Bowman re: Updated "Cheat Sheets" | No objection | |
| 115 | AZ0096293 | | Draft Letter to Ben from Chris Bowman | No objection | |
| 116 | AZ0428238-62 | | Zoladex Strategic Summary 1997-2001 prepared by Keith Patterson | No objection | |
| 117 | AZ0004734-55 | 4/20/95 | Zoladex Strategic Plan 1996-2000 – Draft #1 by Keith Patterson | No objection | |
| 118 | AZ0010334-37 | 1/12/95 | Memorandum to Chris Iacono from Keith Patterson re: Zoladex Pricing Strategy | No objection | |
| 119 | AZ0010297-302 | 3/1/95 | Memorandum to William Simpson from Keith Patterson re: Zoladex Pricing | No objection | |
| 120 | AZ0029298-99 | | Handwritten Notes | No objection | |
| 121 | AZ0043915-95 | 11/3/95 | Draft Memorandum to Chris Iacono from Market Strategy & Contract Operations re: Zoladex Pricing and Volume Discount Pricing | No objection | |
| 122 | AZ0017849-51 | 10/24/96 | Internal Memorandum from Mark Reisenauer to Keith Patterson & Steve Strand re: Zoladex Price Increase Recommendation | No objection | |
| 123 | PXL 06595-661 | 12/27/96 | Letter to Keith Patterson from Sean Coakley & Stephanie Wagoner | No objection | AstraZeneca |
| 124 | PXL01040 | 2/15/95 | Letter to Travelers Railroad Medicare from Sean Coakley | No objection | |
| 125 | PXL01045 | 2/23/95 | Letter to Ms. Rita Crook, North Carolina Medicare Part B from Sean Coakley | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--|-------------------|-----------------------------------|
| 126 | PXL01111-13 | 5/2/96 | FOIA request to Kelly Gross, Blue Shield of California from Sean Coakley | No objection | |
| 127 | PXL01116 | 5/14/96 | Letter to Medicare Part B Claims Review from Sean Coakley | No objection | |
| 128 | PXL01731-34 | 7/9/96 | Letter to Laura Brooks from Sean Coakley re: Pricing for Zoladex 3.6 mg (goserelin acetate implant) - HCPS J9202 | No objection | |
| 129 | PXL01702-11 | 8/8/96 | Letter to Irene Michel, Minnesota Medicare Part B from Sean Coakley | No objection | |
| 130 | PXL06662-725PXL0462 6-96 PXL04697-763 PXL04764-824 PXL04825-90 PXL04891-949 PXL04950-5003 PXL05004-65 PXL05117-69 PXL07273-334 PXL05232-328 | | Reimbursement Hotline Monthly Reports Prepared by Parexel for 1997 | No objection | |
| 131 | AZ0419345-48 | | Medicare Review | No objection | |
| 132 | AZ021838 | 10/12/95 | Internal Memorandum from Thomas Chen to Keith Patterson re: Price Increase for Zoladex | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|-------------------|-----------------------------------|
| 133 | AZ0080407-11 | 11/20/95 | Internal Memorandum from Keith Patterson to Chris Iacono re: Zoladex Pricing | No objection | |
| 134 | AZ0376204-17 | | AstraZeneca Urology Representative Training | No objection | |
| 135 | AZ0565611-14 | 1/30/02 | Email to David Brennan & John Freeberry from Rachel Bloom-Baglin re: AWP Spread "White Paper" | No objection | |
| 136 | AZ0096241-42 | 12/5/97 | Email from John Armstrong re: Zoladex Spreadsheet | No objection | |
| 137 | AZ0413687-91 | 3/7/02 | Fax to Soleil Chavoshi from John Armstrong re: Competitive Pricing | No objection | |
| 138 | AZ0423944-50 | | LHRH Cost Comparison | No objection | |
| 139 | AZ0432026-34 | 3/13/01 | Email from John Freeberry re: Change in AWP Spread | No objection | |
| 140 | AZ0449836-50 | 8/9/00 | Email from John Freeberry to Joan McDevitt Re: Redbook | No objection | |
| 141 | AZ0438780-81 | 1/17/00 | Email from Kenneth Smith re: Comparison of 3 month Zoladex & 3 month Lupron (New AWP & Pricing) | No objection | |
| 142 | AZ0016060-74 | | Proposed Zoladex Contracting Strategy | No objection | |
| 143 | AZ0044002-13 | 1/26/96 | Zoladex 3-Month 10.8mg Depot Pricing Proposal | No objection | |
| 144 | AZ0024179-90 | 00/00/95 | Zoladex Prostate Cancer 1995 Operational Plan | No objection | |
| 145 | AZ0021833 | 11/14/95 | Internal Memorandum to Keith Patterson from Chris Iacono re: Zoladex | No objection | |
| 146 | AZ0040464 | 11/4/97 | Internal Memorandum to C. J. Iacono from M. L. Rickards re: 1998 Pricing Recommendations – Prostate Cancer Portfolio | No objection | |
| 147 | AZ0000134-43 | | Zoladex Strategic Plan 1993-1997 | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------|-----------------------------------|
| 148 | AZ0097294-95 | 6/24/97 | Email from John Armstrong to Timothy Arenson re: 1998 Price Positioning | No objection | |
| 149 | AZ0095847-53 | 11/5/97 | Email from John Armstrong to Jean Ludwig, Kenneth Smith and John Wawrzynek re: Zoladex vs. Lupron Cost & Profit Comparison | No objection | |
| 150 | AZ0424496-98 | 3/27/98 | Internal Memorandum from Sales & Marketing Management Team for Zoladex & Casodex re: Competitive Pricing for Flutamide and Leuprolide | No objection | AstraZeneca |
| 151 | AZ0044713-14 | 11/3/97 | Email from Dean McAlister to Timothy Arenson re: Response: ZOLPRICE93.xls | No objection | |
| 152 | AZ0438474-76 | 2/15/01 | Email from Jeffrey McVey to Ronald Danhoffer re: Highmark Lupron/Zoladex Letter | No objection | |
| 153 | | | Call Notes | No objection | |
| 154 | AZ0010394-99 | 3/3/94 | Memorandum from Keith Patterson to W.J. O'Shea re: Zoladex Quantity Discount Recommendations | No objection | |
| 155 | PXL03686-715 | | Guide to Coverage and Reimbursement | No objection | |
| 156 | AZ0000062-85 | 6/21/94 | Draft #1 Zoladex Strategic Plan 1995-1999 | No objection | |
| 157 | AZ0427246-65 | 7/7/97 | Proposed Zoladex Contracting Strategy | No objection | |
| 158 | AZ0032538-43 | 2/17/95 | Memorandum to William Simpson from Keith Patterson re: Zoladex Pricing | No objection | |
| 159 | PXL02766-812 | | Zoladex Coverage & Reimbursement Physician's Office Guide | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------|-----------------------------------|
| 160 | AZ0428327-50 | | Zoladex Strategic Summary 1998-2002 | No objection | |
| 161 | AZ0017131-36 | 1/23/96 | Internal Memorandum from Keith Patterson to Chris Iacono re: Zoladex Pricing Recommendations | No objection | |
| 162 | AZ0021679-81 | 12/2/96 | Internal Memorandum from Mark Reisenauer re: Zoladex Price Increase | No objection | |
| 163 | AZ0022136-46 | 2/00/96 | US Business Review – February 1996 – Zoladex prepared by Keith Patterson | No objection | |
| 164 | PXL00095-96 | 7/17/96 | Memo to Keith Patterson, Mark Reisenauer, Tom Chen from Howard Tag re: Medicare Reimbursement | No objection | |
| 165 | AZ0010338-39 | 1/19/95 | Internal Memorandum from Keith Patterson to Chris Iacono re: Zoladex Pricing | No objection | |
| 166 | AZ0715813-943 | | Price Analysis | No objection | |
| 167 | AZ0463627-29 | 1/28/02 | Email from Jill Krating to Erik Schultz re: NEW PDF of Pricing News | No objection | |
| 168 | AZ0464857-59 | 3/1/02 | Email from Erik Schultz to Jill Krasting re: AWP Spread | No objection | |
| 169 | AZ0373269 | 3/17/97 | Fax to Frederick Hollon, M.D. from Jack Wawrzynek | No objection | |
| 170 | AZ0096737-38 | 12/1/97 | Fax to Jeffrey Frankel, M.D. from Jack Wawrzynek re: Zeneca Annual Zoladex Contract | No objection | |
| 171 | AZ0094769 | 9/5/97 | Email from Cathy Chakos to Kenneth Smith & John Wawrzynek re: Fay Alliance | No objection | |
| 172 | AZ0437244-47 | 3/30/99 | Email from John Wawrzynek to Todd Orsi re: Annual Contract | No objection | |
| 173 | AZ0373195 | | AstraZeneca Code of Conduct (CD) | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|--|-----------------------------------|
| 174 | | | Video Deposition of Dr. Robert A. Berkman | Relevance FRE 403 | AstraZeneca |
| 175 | | 4/4/06 | Amended Version of AstraZeneca Pharmaceuticals LP's and Zeneca, Inc.'s Responses to Plaintiff's Interrogatories and Requests for Admission in Montana | Relevance | AstraZeneca |
| 176 | | 4/9/04 | Answer of Bristol-Myers Squibb Company, Oncology Therapeutics Network Corporation and Apothecon, Inc. to Plaintiffs' Amended Master Consolidated Class Action Complaint (Excerpts Only) | No objection if entire answer is offered | BMS |
| 177 | | 7/26/04 | Defendant BMS's Responses to Plaintiffs' Interrogatories to the Fast Track Defendants | No objection | |
| 178 | | 1/19/04 | Responses and Objections of Defendants Bristol-Myers Squibb Company, Oncology Therapeutics Network Corporation and Apothecon, Incorporated to Plaintiffs' Request for Production of Documents and Interrogatories (Excerpts Only) | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|------------------|---|---|-----------------------------------|
| 179 | BMS/AWP/0 00092170- 86; BMS/AWP/0 000468-77; BMS/AWP/0 005335-51; BMS/AWP/0 030828-42; BMSAWP/0 017275-78; BMS/AWP/0 00092406; BMS/AWP/0 1071969-70 BMS/AWP/0 030824-25 | Various Dates | Composite exhibit of various letters to publishers from BMS | No objection | |
| | BMS/AWP/0 000468-77 | | | Object to Apothecon prices, relevance, FRE 403; see BMS <u>in limine</u> motion re Apothecon | BMS |
| | BMS/AWP/0 005335-51 | | | Object to Apothecon prices, relevance, FRE 403; see BMS <u>in limine</u> motion re Apothecon | BMS |
| | BMS/AWP/0 030828-42 | | | No objection | |
| | BMSAWP/0 017275-78 | | | Relevance FRE 403; refers only to drugs not in the case | BMS |
| | BMS/AWP/0 00092406 | | | No objection | |
| | BMS/AWP/0 1071969-70 | | | Relevance FRE 403; refers only to drugs not in the case | BMS |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------------|-------------|---|---|-----------------------------------|
| | BMS/AWP/0 030824-25 | | | No objection | |
| 180 | BMS/AWP/0 00186646-49 | 8/22/95 | Price Increase/Decrease Notification Process | No objection | |
| 181 | BMSAWP/0 005609-22 | | Red Book Product Listing Verification | No objection | |
| 182 | BMSAWP00 05571-608 | | Red Book Product Listing Verification | Relevance; FRE 403; refers to Apothecon drugs; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 183 | BMSAWP00 11245-48 | | Letters from Kaszuba to publishers changing markup factor | No objection | |
| 184 | | 9/18/04 | Affidavit of Denise M. Kaszuba | No objection | |
| 185 | BMS/AWP/0 041865-69 | 5/28/93 | Memo from S. Tarriff to “List” re: List Price Increase Oral Antibiotics | Relevance; FRE 403; refers to Apothecon drugs; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 186 | BMS/AWP/0 00275052-59 | | Glucophage XR Price Increase | Relevance FRE 403; refers only to drugs not in the case | BMS |
| 187 | BMS/AWP/0 1109780-84 | 4/22/02 | Email from Greg Fersko to various attaching Powerpoint slides | No objection | |
| 188 | BMS/AWP/0 0337637-41 | | Pricing procedures | Relevance; FRE 403; refers to Apothecon drugs; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 189 | BMS/AWP/0 1088203-11 | 4/30/02 | Email from Leigh Anne Leas to various attaching Powerpoint slides | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|---|---|-----------------------------------|
| 190 | BMS/AWP/0 1112957-82; BMS/AWP/0 1190197- 222; BMS/AWP/0 1071974- 2011 | | Composite exhibit of three Internal Price Lists | Object to extent document relates to drugs not in the case; also object to 1072001-2011 which refers to Apothecon drugs; relevance; FRE 403; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 191 | BMSAWP/0 011361-67 | | Pocket Reference Price List | Relevance | BMS |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|---|-------------------|-----------------------------------|
| 192 | BMSAWP/0 028888-87 (May/June 1994); BMSAWP/0 028868-79 (November/ December 1994); BMS/AWP/0 00095588- 611 (January/Feb ruary 1997); BMS/AWP/0 00095612-23 (March/April 1997); BMS/AWP/0 00095624-35 (May/June 1997); BMS/AWP/0 00095636-47 (July/August 1997); BMS/AWP/0 00095648-63 (September/ October 1997); BMS/AWP/0 000955559- 900 (January/Feb ruary 1998); BMS/AWP/0 00095901-16 (March/April 1998); BMS/AWP/0 00095664-79 (May/June 1998); BMS/AWP/0 00095804-19 (September/ October 1998); BMS/AWP/0 00095820-36 (November/ December 1998) | | Composite exhibit of issues of OTN <i>The Network News</i> | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|---|--|-----------------------------------|
| | BMS/AWP/0 00095699- 714 (March/April 1999); BMS/AWP/0 00095715-30 (May/June 1999); BMS/AWP/0 00095731-46 (September/ October 1999); BMS/AWP/0 00095766-83 (November/ December 1999); BMS/AWP/0 00095747-65 (April 2000); BMS/AWP/0 00095784- 803 (May 2000); BMS/AWP/0 00095861-84 (August 2000) | | | | |
| 193 | BMS/AWP/0 01486072- 73, 001486090 | | OTN AWP Price Report | Authenticity Incomplete | BMS |
| 194 | BMS/AWP/0 00469286-99 | | Executive Summary | No foundation Hearsay Not prepared by BMS | BMS |
| 195 | BMS/AWP/0 1327211 | | AWP (Ain't What's Paid) | Lack of foundation | BMS |
| 196 | BMS/AWP/0 1088191-202 | | Understanding AWPs | No objection | |
| 197 | BMS/AWP/0 00096632-43 | 7/11/00 | Reimbursement in Office Based Oncology | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------------------|-------------|---|---|-----------------------------------|
| 198 | BMS/AWP/0 00393437- 464 | | Reimbursement | Authenticity; incomplete document; lack of foundation; unclear as to whether authored by BMS; source of document unclear; hearsay | BMS |
| 199 | BMS/AWP/0 00096900-12 | 4/6/00 | Memo from Barbara Nathan to John Akscin, among others | No objection | |
| 200 | BMS/AWP/0 00094558- 603 | | BMS Portfolio Marketing Strategy Marketing Choices | Unidentified handwriting; lack of foundation | BMS |
| 201 | BMS/AWP/0 00153461 | 12/5/97 | Memorandum from Ron Miller to Mark Durand re: Oncology Policy Issues, | No objection | |
| 202 | BMS/AWP/0 00071159-62 | 1/10/03 | Email from Barnard to various | No objection | |
| 203 | BMS/AWP/0 00056970- 70150 | | Taxol contract sales | Lack of foundation | BMS |
| 204 | BMS/AWP/0 00096291- 300 | 3/19/03 | Oncology Customer Contract Proposal and Consorta contract pricing | No objection | |
| 205 | BMS/AWP/0 00096333-45 | 1/16/03 | Oncology Customer Contract Proposal and Owen contract pricing | No objection | |
| 206 | BMS/AWP/0 0979750-803 | 1/17/03 | Email from Barnard with Premier contract pricing | No objection | |
| 207 | BMS/AWP/0 1124131-56 | 3/16/03 | Email from Barnard with MHA contract pricing | No objection | |
| 208 | BMSAWP/0 011214-35 | | Etopophos Launch Plan | Relevance, plan was not adopted | BMS |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|--|--|-----------------------------------|
| 209 | BMSAWP/0 000597-617; BMSAWP/0 000647-51 | | Various Kaszuba letters and memos | Relevance; FRE 403; documents refer to Apothecon drugs; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 210 | BMSAWP/0 000574-87 | | Albuterol pricing | Relevance; FRE 403; documents refer to Apothecon drugs; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 211 | BMSAWP/0 000095-120 | | Trimox pricing | Relevance; FRE 403; documents refer to Apothecon drugs; see BMS <u>in limine</u> motion re Apothecon | BMS |
| 212 | BMS/AWP/0 00217841-51 | 1/19/02 | Marre email with Premier and Duke contract pricing | No objection | |
| 213 | BMS/AWP/0 00212669-74 | | Blenoxane contract sales | No objection | |
| 214 | BMS/AWP/0 1123962-74 | 3/5/03 | Mayank email with VePesid analysis | No objection | |
| 215 | BMS/AWP/0 00071256-72 | | Christof Marre, "Taxol Generic Strategy Learnings from the U.S." | No objection | |
| 216 | BMS/AWP/0 1190031-55 | 4/7/02 | Sippel email attaching Taxol Opportunity Plan | No objection | |
| 217 | BMS/AWP/0 01501681 | 8/22/01 | Email from Sandy McMahon re: Taxol Questions | No objection | |
| 218 | BMS/AWP/0 0478735-74 | | Livin Beat – Customer Marketing | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--|--|-----------------------------------|
| 219 | BMS/AWP/0 00097131- 37, at 000097134- 36 | | OTN Cost Differential Report | No objection | |
| 220 | BMS/AWP/0 00096965-85 | | BMS Overview: Values Unique to POHMS | No objection | |
| 221 | BMS/AWP/0 00157423-35 | | Taxane Economics: Effect of Dose and Schedule | No objection | |
| 222 | BMS/AWP/0 01502304-38 | | Practice Efficiencies & Quality Care Workshop – Of Special Interest To: Physicians, Nurses, Office Managers, Billers | No objection | |
| 223 | BMS/AWP/0 00192875-76 | 1/30/01 | Email from Janine Suscewicz transmitting Jan 26 Memo and accompanying BMS interrogatory responses to which the documents were attached | No objection | |
| 224 | BMS/AWP/0 01491629-32 | | Composite exhibit of Soule spread marketing documents | No objection | |
| | Soule Dep. Ex. 8 | | | Lack of foundation, hearsay as to unidentified handwriting | BMS |
| | BMS/AWP/0 01494633 BMS/AWP/0 01491634 BMS/AWP/0 01491635 BMS/AWP/0 01491378-80 | | | No objection | |
| 225 | BMS/AWP/0 01508047-61 BMS/AWP/0 01508114-17 | | Composite exhibit of Davidson spread marketing docs | No objection | |
| 226 | BMS/AWP/0 1233083-184 | 3/18/03 | Greg Bell/Charles River Associates email attaching docs including Paraplatin Deconversion Powerpoint | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------------|-------------|--|---|-----------------------------------|
| 227 | BMSAWP/0 028479-86 | 1/1/95 | BMS-OTN sales agent agreement | No objection | |
| 228 | BMS/AWP/0 01483218-27 | 4/22/03 | Marsha Peterson email and business plan | No objection | |
| 229 | BMS/AWP/0 1FRE 403078 | | Composite exhibit of call notes | No objection | |
| | BMS/AWP/0 1406365 | | | No objection | |
| | BMS/AWP/0 1404191 | | | No objection | |
| | BMS/AWP/0 1404200 | | | No objection | |
| | BMS/AWP/0 1404123 | | | No objection | |
| | BMS/AWP/0 1408993 | | | No objection | |
| | BMS/AWP/0 1408985 | | | BMS objects; duplicate of 1408993 | BMS |
| | BMS/AWP/0 1402293 | | | No objection | |
| | BMS/AWP/0 1409167 | | | No objection | |
| | BMS/AWP/0 1402215 | | | No objection | |
| | BMS/AWP/0 1418108 | | | No objection | |
| | BMS/AWP/0 1418525 | | | No objection | |
| | BMS/AWP/0 1418646 | | | No objection | |
| | BMS/AWP/0 1418692 | | | No objection | |
| | BMS/AWP/0 1418664 | | | No objection | |
| | BMS/AWP/0 1414388 | | | Lack of foundation; hearsay; author not identified | BMS |
| | BMS/AWP/0 1415895 | | | No objection | |
| | BMS/AWP/0 1414599 | | | No objection | |
| | BMS/AWP/0 1414604 | | | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------------|-------------|--------------------|---|-----------------------------------|
| | BMS/AWP/0 1414608 | | | No objection | |
| | BMS/AWP/0 1402192 | | | No objection | |
| | BMS/AWP/0 1402277 | | | No objection | |
| | BMS/AWP/0 1415362 | | | No objection | |
| | BMS/AWP/0 1421942 | | | No objection | |
| | BMS/AWP/0 1423009 | | | No objection | |
| | BMS/AWP/0 1FRE 403078 | | | No objection | |
| | BMS/AWP/0 1421479 | | | Lack of foundation; hearsay; author not identified | BMS |
| | BMS/AWP/0 1420643 | | | No objection | |
| | BMS/AWP/0 1402251 | | | No objection | |
| | BMS/AWP/0 1414566 | | | No objection | |
| | BMS/AWP/0 1426459 | | | No objection | |
| | BMS/AWP/0 1406236 | | | Lack of foundation; hearsay; author not identified | BMS |
| | BMS/AWP/0 1407052 | | | Lack of foundation; hearsay; author not identified | BMS |
| | BMS/AWP/0 1FRE 403600 | | | Lack of foundation; hearsay; author not identified | BMS |
| | BMS/AWP/0 01491764-68 | | | No objection | |
| | BMS/AWP/0 01491769-71 | | | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|---|---|-----------------------------------|
| | BMS/AWP/0 01491859-63 | | | No objection | |
| | BMS/AWP/0 01491646 | | | No objection | |
| 230 | BMS/AWP/0 00056952-69 | 11/1/02 | Pricing & Institutional Operations Overview | No objection | |
| 231 | BMS/AWP/0 01502339 | 3/4/02 | Memo from Denning to Keighley | No objection | |
| 232 | BMS/AWP/0 00956887, BMS/AWP/0 00083788- 839 | 2/4/03 | Akscin email attaching “Law & Order: OBO” PowerPoint | No objection | |
| 233 | BMSAWP/0 005551-70 | 3/4/94 | Fax from MediSpan with AWP _s | No objection | |
| 234 | BMS/AWP/0 00217958-90 | | OBO Opportunities | No objection | |
| 235 | MDL- OBI0000762 8 | 12/7/00 | Letter from Robert Savage re: Correspondence from Pete Stark | Incomplete (missing MDL- OBI00007629) [See Ex. 2780] | J&J |
| 236 | MDL- OBI000FRE 40389-90 | 08/00/00 | Email from Catherine Piech re: Amgen AWP Spread Change to 25% | No objection | |
| 237 | WKh77797- 801 | 2/13/97 | Price Change Notifications | Hearsay Not properly authenticated/ lacks proper foundation | J&J |
| 238 | WKh 02434- 438 | 1/6/98 | Urgent – Price Change Information | Hearsay | J&J |
| 239 | WKh 02446- 447 | 1/7/00 | Price Change | Hearsay | J&J |
| 240 | MDL- OMP004979 8 | | Ortho Biotech Inc. Pricing Strategy | Not properly authenticated/ lacks proper foundation | J&J |
| 241 | | | Contracting Initiatives | No objection | |
| 242 | MDL- OBI0005888 8-923 | | 1998 Reimbursement Update and Challenges | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------|-------------|--|--|-----------------------------------|
| 243 | MDL-OBI0000664 1-98 | 6/21/99 | Document titled "Shaping the Reimbursement Environment for Procrit: Ortho-Biotech, Inc. Discussion Document June 21, 1999" | Hearsay | J&J |
| 244 | MDL-OBI0000837 4-75 | 11/7/00 | Memorandum from John Dempsey to Gary Reedy and Bill Pearson re: Price Increase | No objection | |
| 245 | MDL-OBI0006364 3 | | Physician Economic Impact: Procrit vs. Transfusions RED ALERT | Not properly authenticated/ lacks proper foundation Hearsay FRE 403 | J&J |
| 246 | MDL-OBI0001215 8 | | Oncology Franchise Objections & Responses | No objection | |
| 247 | MDL-OBI0005413 -15 | | POA 3 District Manager Pre-Work | No objection | |
| 248 | | | Charts regarding Procrit | No objection | |
| 249 | MDL-CEN000027 17-878 | 3/25/98 | Remicade cA2 Marketing Plan U.S. Crohn's Indication Launch | No objection | |
| 250 | WKH 01029 | 9/1/98 | Letter Ron Krawczyk to Kathy Gutegesell at FirstData Bank | Hearsay | J&J |
| 251 | MDL-CEN000210 66 | 4/3/01 | Email from Joseph Scodari to Dave Holveck re: AWP Issue-Discussion with Shannon Salmon | No objection | J&J |
| 252 | MDL-CEN000034 78-500 | | Remicade Office Based Infusion Guide | No objection | J&J |
| 253 | MDL-CEN000036 07-73 | 00/00/00 | Practice Management Program for Remicade | No objection | J&J |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------|-------------|---|--|-----------------------------------|
| 254 | MDL-CEN000902 85-302 | 12/18/03 | Powerpoint titled "Local Payer Information" Laura Glassco- National Account Manager, Ken Wegner- Regional Account Manager; Centocor, Inc. | No objection | |
| 255 | MDL-OBI0005490 9-13 | 6/15/92 | Pharmaceutical Sales Agreement with Caremark | No objection | |
| 256 | MDL-OBI0005507 8-82 | 1/7/93 | Pharmaceutical Sales Agreement with Stadtlanders | No objection | |
| 257 | TAP GB 08146 | 6/8/94 | Memorandum to Alan MacKenzie re: Medicare Proposal | Hearsay Not properly authenticated/ lacks proper foundation Relevance | J&J |
| 258 | DD 0081-82 | 6/21/95 | Memorandum to Don Patton from Alan MacKenzie re: Meeting with Ann Vickery of Hogan and Hartson | Hearsay Not properly authenticated/ lacks proper foundation Relevance | J&J |
| 259 | MDL-OBI0005884 2-44 | 1/7/98 | Email from Cathleen Dooley | No objection | |
| 260 | MDL-CEN000085 404-05 | 7/6/99 | Memorandum from Centocor's Michael Ziskind to Jason Rubin | No objection | |
| 261 | MDL-CEN001080 51-54 | 11/5/98 | Letter to C. Klaye Riley from Valerie | No objection | |
| 262 | MDL-OBI0006105 2-053 | 12/2/97 | Memorandum from C. Dooley to G. Reedy | No objection | |
| 263 | MDL-OMO004963 8-39 | 12/3/97 | Memorandum from Gary Reedy to Carol Webb | No objection | |
| 264 | MDL-CEN000711 34 | | Computer Screen Printout | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--|--|-----------------------------------|
| 265 | MDL-OBI0003067 5-84 | 4/10/01 | Letter to Alpine Hematology Oncology from Elaine King | No objection | |
| 266 | YOUNG000 1-11; YOUNG021 3-16 | | Monthly Checks Written by the Youngs and a Couple of Receipts | Relevance Illegible or indecipherable | J&J |
| 267 | YOUNG005 4; YOUNG005 2; YOUNG003 5 | | Invoices showing Remicade Charges | Relevance Illegible or indecipherable | J&J |
| 268 | MDL-OBI0006365 6-57 | 7/10/96 | Memorandum to Minneapolis District from John Hess | No objection | |
| 269 | MDL-OBI0006364 4-55 | 3/22/95 | Bulletin No. 07 to Orlando District from David Rybak re: 1 st Quarter Successes and Team Experiences | No objection | |
| 270 | MDL-OBI0006250 7-661 | 12/1/92 | From Mycrocytic Cells to Macrocytic Sales – Regional Training Workshop Materials held in Houston, Texas | No objection | |
| 271 | MDL-CEN000086 707-777 | | “The Power Within” – Remicade Powerpoint | Illegible | J&J |
| 272 | MDL-CEN000902 83-302 | 11/1/00 | E-mail from Laura Glassco to Tom Weiss, et al. re Dr. Kassan with attached PowerPoint titled “Local Payer Information” Laura Glassco- National Account Manager, Ken Wegner- Regional Account Manager; Centocor, Inc. | No objection | |
| 273 | MDL-CEN001073 60 | | PowerPoint – first slide titled “Topics” | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------------|-------------|---|-------------------|-----------------------------------|
| 274 | MDL-CEN000900 81-84 | 8/20/99 | Document titled "Cost Comparison of Anti-TNF Agents in Rheumatoid Arthritis Patients Receiving Methotrexate for Plan and Group Managers" | No objection | |
| 275 | MDL-CEN000711 33-45 | 5/21/00 | E-mail from Laura Glassco to Darla Ivey, et al. re Stuff with attached document titled: "Cost Comparison of Anti-TNF Agents in Rheumatoid Arthritis Patients Receiving Methotrexate for Plan and Group Managers" dated 8/20/99 and spreadsheets | No objection | |
| 276 | MDL-CEN001073 82-83 | 1/00 | Document titled "Practice Management Worksheet for Assessing New Services" | No objection | |
| 277 | MDL-CEN001073 84 | 7/30/99 | Document titled "Average Reimbursement for Remicade (infliximab) When Billed by a Physician's Practice" | No objection | |
| 278 | MDL-CEN001073 85-89 | | Document titled "Breaking the Barriers: Essential Tools for Remicade Therapy" | No objection | |
| 279 | MDL-CEN000304 66 | 3/16/98 | Interoffice correspondence from Matthew J. Carpenter to J. McHugh and J. Kerrigan re: "Average Acquisition Price vs. Average Acquisition Price" with attached memo from Brian Fitzpatrick to Matt Carpenter re: "AWP vs. Acquisition Pricing" dated 3/13/98 | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|----------------------------|-------------|--|-------------------|-----------------------------------|
| 280 | MDL-CEN000040 03-08 | 11/18/98 | Memo from John McDermott and Alex Shipman to Mary Fisher and Gary Conte re: "Additional Information on AWP Spread" | No objection | |
| 281 | MDL-CEN001036 88-90 | 9/22/02 | E-mail from Seth Fischer to Joseph Scodari, et al. re: "AWP Reporting issue: an overview" | No objection | |
| 282 | MDL-CEN000546 41-43 | 5/3/02 | E-mail from Michael Ziskind to John Hoffman re: "25% policy analysis1.xls – FINAL FINAL CORRECTION? Ignore prior emails" with attached spreadsheet | No objection | |
| 283 | MDL-CEN000041 44-65 | 6/3/99 | PowerPoint – "Presentation to Area Business Managers Mid-Year Recap and Strategy for REMICADE June 3, 1999 Mike Ziskind" | No objection | |
| 284 | MDL-CEN001036 57 | | Document titled "Analysis of Costs for Office IV Administration" | No objection | |
| 285 | MDL-CEN000247 08-09 | 8/20/99 | Document titled "Cost Comparison of Anti-TNF Agents in Rheumatoid Arthritis Patients Receiving Methotrexate for Plan and Group Managers" | No objection | |
| 286 | MDL-CEN00010F RE 403 | 3/1/00 | Letter from Mike Ziskind to Terri Factora | No objection | |
| 287 | MDL-CEN0000FR E 4039-40 | 6/18/99 | Letter from Mike Ziskind to Holli Marchino with fax cover | No objection | |
| 288 | MDL-CEN000447 67-68 | 11/00 | Letter from Michael Ziskind to Dear Healthcare Provider with attached "Payer Policy Update Questionnaire for REMICADE (infliximab)" | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|--|-------------------|-----------------------------------|
| 289 | | 2/15/00 | Software and document titled "Remicade Practice Management Assistant" | No objection | |
| 290 | MDL-CEN000148 40-63 | 1/00 | Document titled "Managed Care Contracting Guide Integrating Infusion Therapies Into Your Practice" | No objection | |
| 291 | MDL-CEN000455 82-85 | 4/3/02 | E-mail from Karen Smith to Michael Ziskind re: "In response to your question" | No objection | |
| 292 | MDL-CEN000004 50-57 | 5/18/01 | Interoffice memo from Mike Ziskind to Scott Habig re "Pricing change scenario assessment" | No objection | |
| 293 | MDL-CEN000648 95; MDL-CEN0 0064949-59 | 5/15/97 | Cover sheet titled "cA2 Commercialization Strategy Plan" with attached PowerPoint titled "cA2 Commercialization Strategy cA2 Business Model" | No objection | |
| 294 | MDL-CEN000147 46-66 | 3/6/00 | Document titled "Remicade: Physician Practice Management Program" | No objection | |
| 295 | MDL-CEN000704 30-31 | 6/13/01 | Interoffice correspondence from Craig Fraser to Immunology Sales Force, et al. re: "Remicade 3.9% Price Increase" | No objection | |
| 296 | MDL-CEN000764 65-67 | 6/26/01 | E-mail from Julie McHugh to Mary Heino, et al. | No objection | |
| 297 | MDL-CEN000554 12-22 | 7/1/01 | Pharmaceutical Rebate Agreement Between Centocor and John Deere Heath Care, Inc. | No objection | |
| 298 | MDL-CEN000703 84-89 | 7/11/00 | E-mail from Stephen Jacobs to Sharon Hunt, et al. re Corporate Accounts SWAT presentation with attached Remicade slides | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|---|-------------------|-----------------------------------|
| 299 | MDL-CEN000820 84-100 | | PowerPoint "Systems Cheryl Cohen Director of Corporate Accounts" | Illegible | J&J |
| 300 | MDL-CEN000806 91-92 | 4/4/02 | E-mail from Cheryl Cohen to Michael Ziskind, et al. re: "Thoughts re. Infusion rate strategy & tactics" | No objection | |
| 301 | MDL-CEN000361 09-40 | 1/23/02 | E-mail from Cheryl Cohen to Eric Mensh, et al. re "Presentation at our meeting Jan 31, 2002" with attached PowerPoint presentation | No objection | |
| 302 | MDL-CEN000327 30-32 | 8/7/02 | E-mail from Cheryl Cohen to Tom Weiss, et al. re "CIGNA & Aetna USHC Reimbursement Clarification" | No objection | |
| 303 | MDL-CEN000352 94-310 | 8/8/02 | E-mail from Cheryl Cohen to Tom Weiss re: "Business Plan" with attached PowerPoint "Remicade Corporate Accounts 2002 Business Plan" | No objection | |
| 304 | MDL-CEN000327 33-35 | 8/7/02 | E-mail from Cheryl Cohen to Tom Weiss re: "CIGNA & Aetna USHC Reimbursement Clarification" | No objection | |
| 305 | MDL-CEN000420 83 | 6/14/01 | E-mail from Kevin Renahan to Immuno_Sales with attached interoffice correspondence | No objection | |
| 306 | MDL-CEN000711 50-55 | 6/22/01 | Email from Pamela Carpenter re: Updated Worksheets | No objection | |
| 307 | MDL-CEN000002 01; MDL-CEN000004 07-08 | | Letters from Jim Binova re Price Increases for Remicade | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------|-------------|---|-------------------|-----------------------------------|
| 308 | MDL-CEN000282 26-28 | 2/14/01 | Email from Eric Mensh re: Specialty Pharmacy Memo | No objection | |
| 309 | MDL-CEN000282 21-25 | 4/30/01 | Email from Jim Bivona to Tom Weiss re: Top Accounts | No objection | |
| 310 | MDL-CEN000085 169-72 | | Powerpoint Slides – “Regional Account Manager Jim Bivona Centocor Immunology Business Unit – 2001 Business Plan” | Illegible | J&J |
| 311 | MDL-CEN000057 73-827 | 00/00/02 | Remicade Corporate Accounts – 2002 Business Plan – “Abbreviated” | No objection | |
| 312 | MDL-OBI0001164 1-58 | 00/00/98 | Ortho Biotech Inc. – Strategic Customer Group 1998 Business Plan Overview | No objection | |
| 313 | MDL-OBI0000797 1-84 | 11/19/98 | Strategic Customer Group – Integrated Business Plan 1999 | No objection | |
| 314 | MDL-OBI0004320 3-14 | 9/28/99 | Email from James Linzer to Cathleen re: ibpsc92899.ppt | No objection | |
| 315 | MDL-OBI0005930 2-05 | | Physician Medicare Reimbursement Scenarios | No objection | |
| 316 | MDL-OBI0000306 1-81 | 8/8/00 | Integrated Business Plan 2001 – Strategic Customer Group | No objection | |
| 317 | | 6/00/02 | 2003 SCG Strategy Development – Strategic Accounts Department Plan | No objection | |
| 318 | MDL-OBI0000349 2 | 8/24/98 | Email from Cathleen Dooley re: Follow-up of voice mail request | No objection | |
| 319 | MDL-OBI0002623 5-36 | 12/5/01 | Email from Ken Nelson re: Avg. Selling Price/CIA Follow up | No objection | |
| 320 | MDL-OBI0005484 8-51 | 1/31/95 | Pharmaceutical Sales Agreement – January 30, 1995 | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------|-------------|--|-------------------|-----------------------------------|
| 321 | MDL-OBI0005521 8-20 | 2/24/95 | Pharmaceutical Sales Agreement – January 15, 1995 | No objection | |
| 322 | MDL-OBI0002948 4-91 | 1/1/01 | Rebate Agreement Between Dr. Schafer & Ortho Biotech | No objection | |
| 323 | MDL-OBI0005245 5-57 | 4/7/02 | Email from Dick Robbins to John Dempsey re: Big Bet – Distribution | No objection | |
| 324 | MDL-CEN000139 65 | 6/13/01 | Ron Krawczyk of Centocor letter to Alisha Nielsen re announcing a 3.9% Price Increase for Remicade | No objection | |
| 325 | MDL-OBI0003067 7-684 | 3/9/01 | Document titled Rebate Agreement Between Alpine Hematology Oncology and Ortho Biotech Production signed by Thomas C. Hiriak for Ortho | No objection | |
| 326 | JJ-001716-727 | Undated | Document titled REMICADE RA Marketing Plan | No objection | |
| 327 | MDL-CEN001036 86-687 | 9/20/02 | Email from Diane Ortiz to David Sheffield, Alex Gorsky, John Szabo, Louise Mehrotra, Kathy Buto, Jerry Holleman re AWP Reporting issue: an overview | Hearsay | J&J |
| 328 | MDL-CEN000545 64-567 | 7/11/02 | Email from Angel Ortiz, Jr., to Kathy Buto, Cathleen Dooley re ASP Charts with attachments with attachments (cc: Diane Ortiz, Doris Chern, Michele Murphy, Paul Denofio | No objection | |
| 329 | MDL-CEN000444 99-504 | 6/6/01 | Email from Rick Bierly to Tom Weiss, Kirk Barton, Ron Krawczyk, Julie McHugh, Scott Habig, Tony Vernon Dominic Caruso re (Updated) Remicade Price Increase Memo with attachments | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------|-------------|--|---|-----------------------------------|
| 330 | | 11/30/00 | Letter to All Orth Biotech Employees transmitting the Ortho Biotech "Best Practice Guidelines" | No objection | |
| 331 | MDL-OBI0006183 1-41 | 10/3/97 | Procrit Reimbursement Alternatives Presented by Documedics | No objection | |
| 332 | MDL-OBI0006134 6-526 | 10/23/97 | JJHCS Regional Managed Care Training | No objection | |
| 333 | MDL-OBI0006169 2-93 | 11/6/97 | Bulleting No. 17 to Orlando Team from Brian Butler re: President's Cup Strategy Meeting Recap | No objection | |
| 334 | MDL-OBI0000677 7-817 | 12/00/99 | Strategies for Shaping the Reimbursement Environment | Hearsay | J&J |
| 335 | | 4/28/06 | Declaration of Mark E. Duxbury | Hearsay FRE 403 Lacks Personal Knowledge No Opportunity to Cross Examine Improper Lay Opinion | J&J |
| 336 | | | POA I Oncology Account Specific Contracting Pre-Work | Not properly authenticated/ lacks proper foundation FRE 403 | J&J |
| 337 | MDL-OBI0006355 2-56 | | Strategic Plan Worksheet | No objection | |
| 338 | MDL-OBI0005288 3-931 | 11/00/02 | Current Strategies – Discussion Document | Illegible MDL-OBI00052887, 52889, 52893, 52900, 52908, 52915, 52922 | J&J |
| 339 | MDL-OBI0006180 3-07 | 8/6/96 | Memorandum from C. Dooley to T. Amick re: Reimbursement Considerations for Spillover Planning | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------|-------------|--|-------------------|-----------------------------------|
| 340 | MDL-OBI00037345 | 3/28/97 | Letter from Rick Heine to A. Sample, M.D. | No objection | |
| 341 | MDL-OMP0049464 | | Contract Terms Comparison Procrit vs Aranesp | No objection | |
| 342 | MDL-OBI00053911-75 | 6/12/02 | Draft Procrit Contracting: Strategic Response to Aransesp – Working Session | No objection | |
| 343 | MDL-OBI00041457-79 | 9/18/02 | Procrit Physician Office Strategy: Strategic Responses to Aranesp prepared by Charles River Associates | No objection | |
| 344 | | 8/5/02 | Procrit Contracting: Modeling Provider Economics prepared by Charles River Associates | No objection | |
| 345 | MDL-OBI00059688-89 | 8/19/98 | Physician Office Rebate Scenarios | No objection | |
| 346 | MDL-OBI00060859-64 | 2/8/99 | Procrit Medicare Review prepared by Trinity Partners | No objection | |
| 347 | MDL-OBI00059329-41 | 12/15/98 | Procrit Medicare Review prepared by Trinity Partners | No objection | |
| 348 | MDL-OBI00055929 | 8/10/00 | Document titled Ortho Biotech Historical List Price Change Procrit | No objection | |
| 349 | MDL-OBI00038306 | 8/8/02 | Document titled Ortho Biotech Products, L.P. Historical Pricing Actions | No objection | |
| 350 | MDL-OBI00015406 | Undated | Chart titled Practice Economics – Detail of Calculations, List Price Changes, No Rebates | No objection | |
| 351 | MDL-OBI00038425-426 | Undated | Document titled Buy/Bill Physicians and APC | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------|-------------|--|-------------------|-----------------------------------|
| 352 | MDL-OBI0004148 0-482 | Undated | Documents/charts titled Physician contracting current status, Managed Care Contracting, Managed Care Contracting | No objection | |
| 353 | MDL-OBI0005591 5-916 | Undated | Document titled Ortho Biotech Products, L.P. Medicare Reimbursement Analysis re Procrit | No objection | |
| 354 | MDL-OBI0005407 6-081 | Undated | Document titled Current 7% Total Rebate (5% physician rebate + 2% administration fee) Proposed Rebates | No objection | |
| 355 | MDL-OBI0001531 1-312 | 11/7/00 | Memorandum from John Dempsey to Gary Reedy, Bill Pearson re Price Increase – PRO’s & CON’s | No objection | |
| 356 | MDL-OBI0006081 8-822 | 6/19/98 | Memorandum from M. Reese to B. Pearson re Proposed Rebates | No objection | |
| 357 | MDL-OBI0000367 1-824 | 1/26/00 | Ortho Biotech document titled Project PROBIT Final Report | Hearsay | J&J |
| 358 | MDL-OBI0000283 3 | Undated | Documents titled Ortho Biotech Products, L.P. – Price Increase/Change | No objection | |
| 359 | MDL-OBI0000451 5-517 | 8/16/99 | Redbook document titled Product Listing Verification Medical Economics | No objection | |
| 360 | MDL-OBI0005653 4-35 | 11/13/00 | Memo from First Data Bank to Martha Hull re products included in databank | No objection | |
| 361 | MDL-OBI0000283 5 | 9/01 | Memo to All Wholesalers And Distributors re URGENT – PRICE CHANGE NOTIFICATION | No objection | |
| 362 | MDL-OBI0006364 2-643 | Undated | Document titled Physician Economic Eimpact: Procrit vs. Transfusions | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------------|-------------|---|-------------------|-----------------------------------|
| 363 | MDL-OBI0005897 9-82 | 9/28/98 | Document titled Objection Workshop | No objection | |
| 364 | MDL-OBI0005916 4 | 9/28/98 | Letter from Brock Weathers to Michael Kalson of Academy Orthopaedics attached | No objection | |
| 365 | MDL-OBI0006178 5 | 4/3/97 | Memorandum from M. Klein/ C. Dooley to S. Salmon | No objection | |
| 366 | MDL-OBI0006310 0 | 8/00 | "POA3" Training (Video) | No objection | |
| 367 | MDL-OBI0005464 7 | | Procrit (Epotein alfa): The Strength of Experience | No objection | |
| 368 | MDL-OBI0005465 0 | | Maximum Value Programs for Preferred Physician Customers | No objection | |
| 369 | | | Maximum Value Programs for Preferred Hospital Customers | No objection | |
| 370 | MDL-OBI0005465 9 | 2002 | Procrit-CA-R 1.2CD-Rom: The Procrit vs. NESP Cost Analysis Presentation-R | No objection | |
| 371 | MDL-JJ0000060- 61 | 9/20/06 | Email from Diane Ortiz re: AWP Reporting Issue: An Overview | No objection | |
| 372 | MDL-CEN000648 85-94 | 3/19/03 | Memorandum to Christine Poon & Bill Weldon from Joe Scodari re: Centocor Price Recommendation – April 7, 2003 | No objection | |
| 373 | MDL-CEN000697 47-50 | 7/12/02 | Email from Kathy Buto re: Updated Slides for July 16 Meeting | No objection | |
| 374 | | | NOT USED | | |
| 375 | FDB-AWP 03929-932 | 12/3/01 | Mailgram to Customer from Frank Dilascia | FRE 403 | SP/W |
| 376 | WCT002398 1 | | | FRE 403 | SP/W |
| 377 | WCT001207 3 | 9/21/95 | Letter to Bill Folk from Jerome Sherman | FRE 403 | SP/W |
| 378 | SPF0057742 | | Letter from Frank Dilascia | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------|-------------|---|---------------------------------|-----------------------------------|
| 379 | SW0173547 | 11/18/97 | Letter from Harvey Weintraub to Jacob Blatt | FRE 403 | SP/W |
| 380 | WAR002064 9 | 10/9/98 | Price Change | FRE 403 | SP/W |
| 381 | SPF0001332 9-31 | 3/19/01 | Email exchange between Olav Hellebo and Peter McCarthy | FRE 403 | SP/W |
| 382 | SPF0116590 -91 | 9/29/00 | Email from Susan Lund to George Paliotto | Relevance FRE 403 | SP/W |
| 383 | SPW003932 9 | 12/11/95 | Memorandum to R. Bucko from D. Reich re: Warrick Inhaler Invoicing | FRE 403 | SP/W |
| 384 | | | Schering-Plough Annual Spreads 1991 to 2004 Q1 | Relevance Hearsay Daubert | SP/W |
| 385 | SPF0115322 -27 | 8/16/00 | E-mail from Kathleen Taylor to Bonnie Zell | Relevance | SP/W |
| 386 | SPF0114601 -05 | 6/20/00 | E-mail from Susan Lund to Patricia Grote re: Reimbursement Letter | Relevance | SP/W |
| 387 | SPF0117637 -38 | 11/3/00 | E-mail from Tomas Manos to Cynthia McGuiness | Relevance | SP/W |
| 388 | SPF0118419 -26 | 1/4/01 | E-mail from Denise Foy to Ray Russo re: Revised Q&A for Genentech Announcement | Relevance | SP/W |
| 389 | SPF0105089 -92 | 7/27/98 | E-mail from Frances Deangelo-Lynch to Bruce Wallace re: Kaiser Files | Relevance | SP/W |
| 390 | SPW004254 6 | | Schering Integrilin Committed Member Program – Letter of Commitment | Relevance | SP/W |
| 391 | SPF0119115 -16 | 7/2/01 | E-mail from Janice Brennan to Alberto Sanabria re: New Integrilin NDPs and AWPs | Relevance | SP/W |
| 392 | SPF0113276 -300 | | E-mail from Susan Lund to George Paliotto re: Current Reimbursement Status of 3b/3a Class | FRE 403 Hearsay | SP/W |
| 393 | SPF0074932 -35 | 8/19/99 | E-mail from Gary Galvan to Peter Kamins re: Temodar | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------------|-----------------------------------|
| 394 | SPF0104510-12 | 2/2/98 | E-mail from David Maya re: Intron 95% AWP Reimbursement for Bladder | Relevance | SP/W |
| 395 | SPW0042545 | | Schering Intron Committed Member Program – Letter of Commitment | FRE 403 | SP/W |
| 396 | WAR0006979-82 | | CVS Proposal | FRE 403 Incomplete | SP/W |
| 397 | SW0027026 | | Schering document titled “Cost Analysis for Superficial Bladder Cancer” | Relevance | SP/W |
| 398 | WAR 0065610-13 | 4/29/03 | Letter to Michelle Sylvestre from B. Michael Kennedy re: Schering Corporation Pricing | No objection | |
| 399 | SPF0104512 | | Intron A for Superficial Bladder Carcinoma | Relevance Incomplete | SP/W |
| 400 | SPW0039766-836 | | Schering Laboratories Generic Strategy | FRE 403 | SP/W |
| 401 | WAR0065608-09 | 4/3/03 | Letter from B. Michael Kennedy to David Parella with Warrick Pharmaceuticals Pricing Update for the month ending 03/31/03 | No objection | |
| 402 | SPW0039331-34 | 4/14/97 | “Rider To Terms Of The Bid” between Warrick Pharmaceuticals and Jack Eckerd Corporation | Relevance | SP/W |
| FRE 403 | FDB-AWP 03988-90 | 11/11/00 | Fax from Peter Kamins to Ina at First Databank with Western Union Mailgram from Frank J. Dilascia to Peter Kamins re: price increases | FRE 403 | SP/W |
| 404 | WAR0000511 | | Document titled “Amerisource Income Rx and Select Market Share Programs” | FRE 403 | SP/W |
| 405 | SW0638402-545 | | Schering-Plough Organizational Chart | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|---------------------------------|-----------------------------------|
| 406 | | 8/29/06 | Press Release "Schering to Pay \$435 Million for The Improper Marketing of Drugs and Medicaid Fraud" | Relevance Hearsay | SP/W |
| 407 | SW0638402-595 | 4/1/00 | April 1, 2000 Schering-Plough International Organization Chart of employees | FRE 403 | SP/W |
| 408 | WAR000599 3-6097 | | Schering Laboratories Generic Strategy | FRE 403 | SP/W |
| 409 | WAR000595 7-77 | 4/21/93 | Proventil Inhaler Generics Strategies | Relevance | SP/W |
| 410 | SPW003967 2-74 | 1/4/93 | Schering Laboratories Memo from Eugene P. Desimone and Richard W. Zahn to Raul E. Cesan re: Strategic Issues | Relevance Lack of Foundation | SP/W |
| 411 | WAR004607 1-72 | 5/10/95 | Schering Labs Managed Care Memo from Beth Voss to Betsy Chorpenning re: Proposal for Suncare, Warrick and Vancenase aerosol at DEMAC>SelectCare | FRE 403 | SP/W |
| 412 | WCT014553 6 | 6/13/00 | Warrick Pharmaceuticals Memo from Harvey Weintraub to Raman Kapur re: Discontinuance of Private Label Product | Relevance | SP/W |
| 413 | WCT014550 4 | 2/6/01 | Schering Laboratories Letter from Michael Marino to Don McGeorge and Mike Schlotman re: Return Policy | Relevance | SP/W |
| 414 | WCT000171 3-16 | 6/24/94 | Revised Schering Laboratories Slides re: Proventil Inhaler | Relevance | SP/W |
| 415 | SW0641705-06 | 3/23/99 | Warrick Memo from Darren K. Willoughby to Raman Kapur re: Updated Managed Care Pricing | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------------------------|--------------------|---|---------------------------------|-----------------------------------|
| 416 | SPW003983 7-38 | | Integration of Warrick into Managed Care summary of review of mission and action plan | FRE 403 Lack of Foundation | SP/W |
| 417 | SW0024512 7-30 | 10/20/99 | Extraneous Costs Associated with Warrick Albuterol Discontinuation from Richard Zahn | Relevance | SP/W |
| 418 | WCT014492 4-28 | 3/29/94 | Schering Managed Care Memo from David Lee to Scott Larson re: GeriMed Warrick Contract Proposal | Relevance Lack of Foundation | SP/W |
| 419 | WAR000166 1 | 12/7/95 | Warrick Sales Meeting Agenda | FRE 403 | SP/W |
| 420 | SW0647978- 8033 | | Contracting Guide | Relevance | |
| 421 | WCT003178 6-90 | 8/9/93 | Schering Laboratories Memo Harvey Weintraub to Richard Zahn re: Status Report – Warrick Pharmaceuticals | FRE 403 Lack of Foundation | SP/W |
| 422 | WAR004314 1-48; WAR004312 4 | 2/2/95 | Warrick Letter to Burt Orland Director of Pharmacy for Fallon re: contract price effective March 1, 1995 through December 31, 1995; and October 28, 1999 email from Patty Burke to Kathleen Flynn re: Fallon Clinic – Albuterol | No objection | |
| 423 | SW0425368- 70 | 5/13/02 | Email from Michael Flinn to Paul Ehrlich re: Impact of Changing Medicaid Basic Rebate Minimum with Schedule Attached | Relevance | SP/W |
| 424 | WAR005401 8; SPF0045824 -26 | 2/8/99; 2/16/99 | E-mail from Frank Finnie re: Albuterol Inhaler Back-Order Status; and E-mail Penny Malcolm to Rosanna Dooley re: CMOP Shipments for Proventil Inhalers | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|--|----------------------------------|-----------------------------------|
| 425 | WAR000615 5-56 | 6/21/00 | Letter from John F. Hoffman to L. Timothy Terry | No objection | |
| 426 | SPF0057682 | 1/8/02 | E-mail from B. Michael Kennedy to John Vanschaften re: Price Reporting | Relevance | SP/W |
| 427 | WCT000262 2 | 12/29/95 | Warrick letter from Phyllis T. Sinoradzki to Sharon Milton-Wilhelm re: Albuterol pricing | Relevance | SP/W |
| 428 | WCT001213 6 | 12/30/95 | Warrick letter from Phyllis T. Sinoradzki to Elizabeth Geary re: Albuterol pricing | Relevance | SP/W |
| 429 | WCT001181 6 | 12/30/95 | Warrick letter from Phyllis T. Sinoradzki to Martha McNeill re: Albuterol pricing | Relevance | SP/W |
| 430 | WAR000143 4-41 | 1/3/96 | Schering-Plough Memo from Mark Calabrese, Carolyn Heinl Kocis and Kevin Cavanagh to Managed Care Directors and MCAMs re: Proventil Inhaler/Albuterol Generic Managed Care Action Plan | FRE 403 Lack of Foundation | SP/W |
| 431 | WAR002242 9 | 2/23/95 | Warrick letter from Harvey J. Weintraub to Warrick Accounts re: Albuterol price increase | FRE 403 Lack of Foundation | SP/W |
| 432 | WAR002966 1 | 5/15/98 | Schering-Plough Memo from B. Michael Kennedy to Raman Kapur re: Rite- Aid Chargeback Program | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|---|-----------------------|-----------------------------------|
| 433 | WAR001511 4; WAR001507 1; WAR001514 3-44; WAR001516 7; WAR001518 9-90; WAR001500 9-10 | | Rite-Aid Corporation Secret Pricing | FRE 403 Incomplete | SP/W |
| 434 | WAR000700 1-02 | | Rite-Aid Pricing | FRE 403 | SP/W |
| 435 | WCT014530 1-06 | 11/30/98 | Warrick letter from Jerome A. Sherman to Irwin Wechsler re: ISMN tablet pricing | FRE 403 | SP/W |
| 436 | WAR002540 5 | 6/6/95 | Warrick letter from Jerome A. Sherman to John Ziebell re: Inhalation Solution and Syrup | FRE 403 | SP/W |
| 437 | WAR002152 9-30 | 9/21/95 | Warrick letter from Al Graf to John Ziebell re: Albuterol Price Increase | FRE 403 | SP/W |
| 438 | WAR002149 8 | 5/8/96 | Memo from Patty Hiley to Yvonne Cagnina re: Walgreen Company Credit, Line Rebate 1st Quarter 1996 | FRE 403 | SP/W |
| 439 | WAR002520 1 | 2/25/98 | Letter Al Graf to John Ziebell re: Albuterol Price and Rebate Change | Relevance | SP/W |
| 440 | WAR002064 3 | 5/5/98 | Warrick Promotion Agreement with Walgreen | FRE 403 Incomplete | SP/W |
| 441 | WAR000671 9-22 | 5/7/98 | Warrick memo Al Graf to Raman Kapur re: Walgreen's Free Goods | FRE 403 | SP/W |
| 442 | WAR002520 2 | 5/22/98 | Letter Al Graf to John Ziebell re: Albuterol Price Change | Relevance | SP/W |
| 443 | WAR002519 5 | 10/9/98 | Letter Al Graf to John Ziebell re: Albuterol Price Change | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|--|---------------------------------|-----------------------------------|
| 444 | WAR002518 0 | 3/11/99 | Letter Al Graf to John Ziebell re: Albuterol Price Change | Relevance | SP/W |
| 445 | WAR002517 4 | 9/22/99 | Letter Al Graf to John Ziebell re: Albuterol Sulfate Price Change | FRE 403 | SP/W |
| 446 | WAR002517 0 | 11/11/99 | Letter Al Graf to John Ziebell re: Albuterol Price Change | Relevance | SP/W |
| 447 | WAR001669 5 | 5/30/96 | CVS/Warrick Inhaler Market Share Program | FRE 403 Lack of Foundation | SP/W |
| 448 | WAR001666 8 | 11/20/96 | Fax Jerome Sherman to Jackie Mobley re: Market Share Program | FRE 403 Lack of Foundation | SP/W |
| 449 | SPW004210 3-04 | 1/29/97 | Letter Penny Malcolm to Anthony Tavolaro re: Chargeback Rebate | FRE 403 | SP/W |
| 450 | WAR001179 9 | 2/18/97 | Letter Jerome Sherman to Anthony Tavolaro re: Albuterol Sulfate Price Change | FRE 403 | SP/W |
| 451 | WAR001163 7-38 | 3/24/97 | Letter Anthony Tavolaro to Jerome Sherman re: Generics | Relevance Hearsay | SP/W |
| 452 | WAR001181 2 | 3/27/97 | Letter Jerome Sherman to Anthony Tavolaro re: Albuterol Price Change | Relevance Lack of Foundation | SP/W |
| 453 | SW0736211- 17 | 6/10/97 | Warrick Fax re: Total Line Rebate Program | FRE 403 | SP/W |
| 454 | WAR001181 1 | 9/9/97 | Warrick letter Jerome Sherman to Anthony Tavolaro re: Albuterol Price Change | Relevance Lack of Foundation | SP/W |
| 455 | WAR001180 0 | 9/9/97 | Warrick letter Jerome Sherman to Anthony Tavolaro re: Albuterol Sulfate Price Change | FRE 403 | SP/W |
| 456 | SPW004207 7-82 | 10/27/97 | Warrick letter to Anthony Tavolaro re: Total Line Rebate Program | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--|-----------------------|-----------------------------------|
| 457 | WAR000645 5-56 | 5/5/98 | Warrick letter Jerome Sherman to Anthony Tavolaro re: Albuterol Price Change | Relevance | SP/W |
| 458 | WAR000644 9-50 | 10/16/98 | Warrick letter Jerome Sherman to Kate Shattuck re: Albuterol Price and Rebate Change | Relevance | SP/W |
| 459 | WAR000645 1-52 | 10/28/98 | Warrick letter Jerome Sherman to Kate Shattuck re: Albuterol Price and Rebate Change | Relevance | SP/W |
| 460 | WAR000643 1 | 1/18/99 | Warrick letter Jerome Sherman to Matt Leonard re: Albuterol Price Change | Relevance | SP/W |
| 461 | WAR000253 3 | 4/12/99 | Warrick Memo Jerome Sherman to Raman Kapur re: Rite Aid/CVS – Wholesaler Chargebacks | FRE 403 | SP/W |
| 462 | WAR002060 9-10 | 6/21/99 | Warrick Fax to Matthew Leonard re: completely executed copy of the Total Line Rebate Agreement | FRE 403 | SP/W |
| 463 | WAR000642 4; WAR000642 6 | 9/14/99 | Warrick letter Jerome Sherman to Matt Leonard re: Albuterol Sulfate Price Change | FRE 403 | SP/W |
| 464 | WAR000642 7 | 9/14/99 | Warrick Account Information Form for Price Change to CVS | Relevance | SP/W |
| 465 | WAR000635 3 | 3/22/00 | Warrick letter Jerome Sherman to Matt Leonard re: Albuterol Price Change | Relevance | SP/W |
| 466 | WAR003070 8-11 | 11/30/00 | Warrick letter to David Marshall re: Chargeback Rebate | FRE 403 | SP/W |
| 467 | WAR000697 9-82; WAR002028 3-86 | | CVS Proposal | FRE 403 Incomplete | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|--|---------------------------------|-----------------------------------|
| 468 | WAR000633 6-37 | 7/5/00 | Warrick Memo Jerome Sherman to Ruth Olivares re: CVS- Meeting Ethex Offer with Warrick Promotion Agreement | FRE 403 | SP/W |
| 469 | WAR003785 1-52 | 1/8/01 | Warrick Promotion Agreement with Merck-Medco | Relevance Lack of Foundation | SP/W |
| 470 | WAR003680 7-09 | 1/16/96 | Schering-Plough Fax Richard Zahn to Raman Kapur re: Medco Proposal | FRE 403 Lack of Foundation | SP/W |
| 471 | WAR000151 0-27 | | Schering/Warrick Albuterol Inhaler Action Plan, prepared by Steve Cooper and Mark Calabrese | No objection | |
| 472 | WCT000103 2 | 1/4/95 | Warrick Memo Steve Cooper to Raman Kapur re: Notes from Trade Sales/Warrick Staff Meeting | FRE 403 | SP/W |
| 473 | SPW003933 6 | 7/11/97 | Schering Corporation Guarantees re: ANDA Generics | Relevance | SP/W |
| 474 | | 3/15/93 | Certificate of Incorporation of Warrick Pharmaceuticals Corporation issued by Delaware Secretary of State | Relevance | SP/W |
| 475 | | 2/22/94 | State of Delaware 1993 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 476 | | 2/23/95 | State of Delaware 1994 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 477 | | 2/15/96 | State of Delaware 1995 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 478 | | 2/21/97 | State of Delaware 1996 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 479 | | 2/24/98 | State of Delaware 1997 Annual Franchise Tax Report for Warrick | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|---|-------------------|-----------------------------------|
| 480 | | 2/17/99 | State of Delaware 1998 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 481 | | 2/21/00 | State of Delaware 1999 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 482 | | 2/21/01 | State of Delaware 2000 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 483 | | 2/21/02 | State of Delaware 2001 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 484 | | 2/26/03 | State of Delaware 2002 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 485 | | 2/3/04 | State of Delaware 2003 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 486 | | 2/23/05 | State of Delaware 2004 Annual Franchise Tax Report for Warrick | Relevance | SP/W |
| 487 | WCT014532 0-37 | 3/22/02 | Schering Corporation Contracts & Pricing fax Kevin Kendell to Raman Kapur re: 1993 Master and Pharmaceutical Pricing Agreements for Secretary of Veterans Affairs and Warrick | Relevance | SP/W |
| 488 | WCT003165 5-56 | 2/3/99 | Memo F. Finnie to J. Caso re: Albuterol Inhaler Back-Order | FRE 403 | SP/W |
| 489 | SPF0084011 -14 | 2/3/00 | Email John Vanschaften to Mark Nolan, Kathleen Flynn, Serafina Oxner and Darren Ray re: Warrick Managed Price List – 1/01/00 | FRE 403 | SP/W |
| 490 | WAR004438 6 | 8/23/99 | Warrick Managed Care Pricing | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------------|------------------------|--|--|-----------------------------------|
| 491 | | 7/16/04 | Warrick letter Janice Brennan to David Parrella re: Warrick Pricing Update for the Month Ending 6/30/04 | Relevance | SP/W |
| 492 | SPF0241686 | 5/5/00 | E-mail Debbie Kane to Greg Birch and others re: Price Alert! | No objection | |
| 493 | SW0466235-36; SPF0222662 | 7/19-20/00; 7/19/00 | Schering Corporation e-mails Janice Brennan to Mike Walsh and Dan Harkins re: AWP Price List Distributions; Schering Corporation e-mails between Janice Brennan and Karen Yutsus re: Req's for Price Lists | No objection | |
| 494 | WCT014506 6-67 | 9/3/93 | Warrick letter Harvey Weintraub to Karen Green re: New Albuterol Sulfate Package Size | FRE 403 | SP/W |
| 495 | WCT014480 9 | 10/12/93 | Warrick letter Harvey Weintraub to Don Rodriguez re: Albuterol Sulfate Price Change | FRE 403 | SP/W |
| 496 | SPF0084328 -33 | 8/14/00 | Warrick email Dan Valerio to Harvey Weintraub re: Redbook Omissions Letter to Linda Panke | FRE 403 | SP/W |
| 497 | SPF0001739 4-95 | 12/10/02 | E-mail Brian Longstreet to Olav Hellebo among others re: Rebetol/Ribavirin Retail Pharmacy Strategy | Relevance | SP/W |
| 498 | WCT000087 9 | 9/8/99 | Letter Bindley Western's Christopher Worrell to Warrick's Al Graf re: manipulation of pricing | Relevance Hearsay Lack of Foundation | SP/W |
| 499 | WCT000128 5-96 | | PowerPoint Slides re: Rebates | FRE 403 | SP/W |
| 500 | WCT000129 7-302 | 10/1/96 | Warrick Market Share Rebate Documentation – Rebates – Procedural Guidelines | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------------------|-----------------------------------|
| 501 | SW0398802-05 | 2/13/02 | Warrick Rebate Programs | FRE 403 | SP/W |
| 502 | SPF0088047-48 | 7/9/02 | E-mail Lilly Kritou to Brian Block and others re: Warrick Rebate Programs | FRE 403 | SP/W |
| 503 | WCT001282 3-24 | | Warrick Individual Prices and Promotion | FRE 403 | SP/W |
| 504 | WCT000127 8-80 | 5/15/98 | Warrick Trade Rebates – Generic Division PowerPoint Presentation by Jackie Mobley | FRE 403 | SP/W |
| 505 | WAR007231 7-36 | | Free Goods Summary | FRE 403 Lack of Foundation | SP/W |
| 506 | WCT014554 7 | 3/31/00 | Warrick and Schering TRAM Enhancement Requirements re: Market Share Rebate Claims | FRE 403 | SP/W |
| 507 | WCT014524 5-48 | 12/12/94 | Warrick letter Walter Gough to Jerry Kern re: Total Line Rebate Program | FRE 403 | SP/W |
| 508 | WCT014517 6-7 | 12/10/93 | Warrick Proposal with Walgreen | FRE 403 | SP/W |
| 509 | WCT014517 8 | 1/3/96 | Warrick letter Jerome Sherman to Bob Breetz re: Albuterol Program | FRE 403 | SP/W |
| 510 | WCT014516 9-72 | 8/4/94 | Warrick letter Walter Gough to Paul Beahm re: Total Line Rebate Program | FRE 403 | SP/W |
| 511 | WCT014531 6-19 | 6/24/99 | Fax Eckerd's Beatrice Vines to Warrick's Paul Thompson re: Executed Total Line Rebate Agreement | FRE 403 | SP/W |
| 512 | SPW004210 7-08 | 8/7/96 | Warrick letter Penny Malcolm to Anthony Tavolaro re: Rebate Program | FRE 403 | SP/W |
| 513 | SPW004210 5-06 | 10/31/96 | Warrick letter Penny Malcolm to Anthony Tavolaro re: Rebate Program | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------|-------------|---|---------------------------------|-----------------------------------|
| 514 | SPW004209 9-100 | 4/25/97 | Warrick letter Penny Malcolm to Anthony Tavolaro re: Rebate Program | FRE 403 | SP/W |
| 515 | WAR000633 0-31 | 4/7/94 | Warrick Albuterol Agreement Terms Schering Sales Accounts | No objection | |
| 516 | WAR000612 3-27 | 7/8/93 | Schering-Plough Memo L. Weiss to Distribution re: draft news release on Warrick | Relevance Lack of Foundation | SP/W |
| 517 | WAR000124 9 | | Reduction of Medicaid Through Use of Generics | Relevance Incomplete | SP/W |
| 518 | WAR000000 1-13 | 4/1/97 | Schering-Plough Organization Chart | FRE 403 | SP/W |
| 519 | WCT016393 9 | 8/6/93 | Contracts & Information Memo Betsy Chorpenning to Richard Zahn re: Warrick Products | Relevance | SP/W |
| 520 | SPW004209 1-93 | 7/7/00 | CFI NJ/Central Fill Application for Generic Contract Award Proposal signed by Michael Kennedy | Hearsay Incomplete | SP/W |
| 521 | WAR000142 2-23 | 11/12/96 | Contracts and Pricing Memo Kimberly Timko to Linda Zhou re: Rebate Impact of BP Changes | Relevance | SP/W |
| 522 | SPF0002274 6 | 10/11/02 | Schering Labs Memo from Richard Zahn re: Pricing SOPs | FRE 403 | SP/W |
| 523 | WCT000167 9-87 | 12/7/00 | Best Price, Medicaid Rebates and Nominal Pricing prepared by Michael Flinn | Relevance | SP/W |
| 524 | SW0098712 | | Pricing definition from Schering-Plough Manual defines Net Direct AWP | Incomplete | SP/W |
| 525 | SPF0077834 -36 | 7/18/02 | E-mail Michael Walsh and others re: Field Trade Account Alignment | FRE 403 | SP/W |
| 526 | SW0159246- 69 | 7/1/99 | Warrick Trade Rebate Claims Log | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|------------------------------------|-----------------------------------|
| 527 | SW0159275-304 | 8/9/99 | Warrick Memo Jesse Mensah to Michael Kennedy re: 1999 Trade Rebate Claims | FRE 403 | SP/W |
| 528 | SW0159402-51 | 12/7/99 | Warrick Memo Jesse Mensah to Michael Kennedy re: 1999 Trade Rebate Claims | FRE 403 | SP/W |
| 529 | WCT014553 7-41 | 5/24/00 | Combined Schering-Plough Report on Warrick/Generic and Brands | Relevance | SP/W |
| 530 | WCT014508 9-90 | | 1998 Schering Division Standard Approval Notice includes Schering-Plough and Warrick signoff | FRE 403 | SP/W |
| 531 | WCT014514 7 | 1/10/96 | Warrick letter Jerome Sherman to Betty Swansinger of Discount Drug Mart re: Proventil Market Share Program, Rebate Programs, and other off-invoice discounts | FRE 403 | SP/W |
| 532 | SPF0329424 -29 | 1/3/02 | E-mail John Vanschaften to Michael Kennedy and Harvey Weintraub re: Warrick Monthly Price Reporting to All States Medicaid and Formulary Offices | No objection | |
| 533 | WAR000138 4-87 | 5/14/99 | Trade Financial Services Memo from M. Nolan re: 1991-1 Medicaid Best Price Changes for Schering and Warrick Products | Relevance | SP/W |
| 534 | WCT006994 3-45 | 5/17/01 | TMS Pricing on Warrick AWPIDs | Relevance Hearsay Incomplete | SP/W |
| 535 | WTI014647 8-81 | 8/6/99 | Warrick Telemarketing Sales Records for 1999 | FRE 403 Hearsay | SP/W |
| 536 | WAR000674 5-48 | 3/6/97 | Warrick letter Louis Manfredi to Thelma Underwood of Arkansas Medicaid enclosing Product Line Report | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------|-------------|---|-------------------|-----------------------------------|
| 537 | WAR007135 4-55 | 6/18/03 | Schering-Plough email Michaela Lukanski to Louisiana and others re: LAM Offer Form | Relevance | SP/W |
| 538 | SW0325880- 81 | 4/27/98 | Memo R. D oliveux to Raul Cesan re: Respiratory Risk Share Proposal and ITG | Relevance | SP/W |
| 539 | SW0425013- 14 | 2/22/99 | Memo Richard Zahn to Raul Cesan re: Cigna Contract Proposal | Relevance | SP/W |
| 540 | SPF0030451 -54 | | Schering Labs Memo Greg Birch and Debbie Kane to Richard Zahn re: Medicare Analysis | No objection | |
| 541 | SW0024555 6-67 | | Chain Store Initiatives | Relevance | SP/W |
| 542 | SW0587249- 62 | 7/11/97 | Memorandum from Joann Androconis to Greg Novell re: Proventil HFA Backgrounder | Relevance | SP/W |
| 543 | SPW003245 6-622 | | Warrick Pharmaceuticals Policy and Procedure Manual | No objection | |
| 544 | SW0723861- 68 | | 1998 Schering Plough 1998 Goals Report-Strategic | Relevance | SP/W |
| 545 | SW0723936- 57 | | 1999 Schering Plough 1999 Goals Report | Relevance | SP/W |
| 546 | SW0723124- 59 | | 1998 Schering Plough Goals Report- 1998 Operating Plan-Financial | Relevance | SP/W |
| 547 | SW0723160- 188 | | 1997 Schering Plough 1997 Goals Report-1997 Operating Plan | Relevance | SP/W |
| 548 | SW0721087 | 4/16/03 | Message from Lisa Davis to Glyndon Kennerly re: CTRA does not state payments for suits. | Relevance | SP/W |
| 549 | SW0721089- 90 | 1/15/03 | Email from Lisa Davis to Karen Klemm, Marilyn Davis re: Check Request Question | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|----------------------|-----------------------------------|
| 550 | SW0721179-82 | 1/7/03 | Check Requests from Schering Plough to Steven O'Day of John Wayne Cancer Institute re Intron A testing. | Relevance | SP/W |
| 551 | SW0721230-35 | | ECAP 2003 Projected Payments (2003 Mo. Trial Bgts) | Relevance | SP/W |
| 552 | SW0721236-8 | | ECAP 2003 TIMS Report 2003 Estimates | Relevance | SP/W |
| 553 | SW0722507-13 | 9/29/99 | Email chain and attached Net Direct Price List from Christine Baker to Joan Crout re: Net Direct Price/Brief Product Description List (price increase Integrelin) | FRE 403 | SP/W |
| 554 | SW0707098-102 | | Temodar Sales Report | FRE 403 | SP/W |
| 555 | SW0707085-9 | | Intron Sales Report | FRE 403 | SP/W |
| 556 | SW0580581-6 | 6/14/00 | Letter and attachments from James Conti Schering Plough) to Robin Zeal (Prescription Solutions) re: 2.5 million rebate for the 1998 through 1999 settlement. | Relevance | SP/W |
| 557 | | 8/29/06 | Complaint United States v. Schering Sales Corporation 06-cr-10250 | Relevance Hearsay | SP/W |
| 558 | | 8/24/06 | Letter from Michael J. Sullivan (US Attorney, District of Massachusetts) to Brien T. O'Connor (Ropes & Gray) re: United States v. Schering Sales Corporation Settlement Agreement | Relevance Hearsay | SP/W |
| 559 | | 8/24/06 | Settlement Agreement between United States of American and Schering Plough Corporation | Relevance Hearsay | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|---------------------------------|-----------------------------------|
| 560 | | 8/25/06 | Addendum to Corporate Integrity Agreement Between the Office of Inspector General of the Department of Health and Human Services and Schering-Plough Corporation | Relevance Hearsay | SP/W |
| 561 | | 8/24/06 | Letter from Michael J. Sullivan (US Attorney, District of Massachusetts) to Brien T. O'Connor (Ropes & Gray) re: Side Letter Agreement with Schering Plough Corporation | Relevance Hearsay | SP/W |
| 562 | | 8/29/06 | Press Release re: Schering to Pay \$435 Million for the Improper Marketing of Drugs and Medicaid Fraud | Relevance Hearsay | SP/W |
| 563 | SPF0254288-444 | 5/7/01 | Email and attachments from Penny Malcom to Christian Nazar, Ronald Martin, Michael Walsh, Peter Kamins, Ronald Martino, Gary Gavan, and Frank Diascia re: Proventil HFA/Lotrisone Lotion Rebate | Relevance | SP/W |
| 564 | SPF0254445-53 | 5/7/01 | Email and attachments from Penny Malcom to Frank Dilascia, Peter Kamins, Ronald Martin, Ronald Marino, Charles McDonald, Galvan Charles, Christian Nazar, and Michael Walsh re: Rebate Program | Relevance | SP/W |
| 565 | SW0579097-103 | | Business Rationale for ITG I.T. Reengineering Investment | Relevance | SP/W |
| 566 | SW0578838-82 | | Overview of Disease Management Program | Relevance Lack of foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|-----------------------|-----------------------------------|
| 567 | SW0578773-6 | 5/14/98 | Schering Plough Account Proposal for Prescription Solutions | Relevance | SP/W |
| 568 | SW0578539-42 | 10/21/99 | Schering Plough Memorandum from Roch Doliveux and Len Camarda re: Managed Care/Health Management Organization | Relevance | SP/W |
| 569 | SW0578756-7 | 6/23/99 | Memorandum from Rich Zahn to Raul E. Cesan re: Protect and Grow Strategy for Foundation Health Systems | Relevance | SP/W |
| 570 | SW0579194 9-81 | 3/29/00 | Roch Doliveux Interview re: Rebates | Relevance Hearsay | SP/W |
| 571 | WCT101454 76 | 5/31/01 | Memorandum from Harvey Weintraub to Mr. R. Cesan re: Albuterol Inhaler-Price Change Recommendation | No objection | |
| 572 | SPF0001723 8-79 | 12/13/01 | Email and attachment from Keith McCormick to Brian Longstreet re: Grants 2000-2001 | FRE 403 | SP/W |
| 573 | SPF0002274 5-46 | 11/2/01 | Schering Plough Memorandum from Richard Zahn to Steve Andrzejewski, Joe Caso, Anne Fields, Bill Heiden, and Jim Mackey re: Product Pricing | No objection | |
| 574 | SW0724651-54 | 4/20/00 | Letter from B. Michael Kennedy to Mr. William Shrigley re: Sales made by Schering Plough to drug repackagers and relabelers | Relevance | SP/W |
| 575 | WAR007296 2-88 | | Spreadsheet Schering-Plough and Warrick Pharmaceuticals | FRE 403 | SP/W |
| 576 | SW0676381 | | Agreement between Schering Corporation and TDI Managed Care Services, Inc. | FRE 403 Incomplete | SP/W |
| 577 | SW0674485-95 | 8/98 | Medicaid Drug Rebate Operational Training Guide | Relevance Hearsay | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|----------------------|-----------------------------------|
| 578 | SW0689920-23 | | OBI Reallocation | Relevance | SP/W |
| 579 | SW0674027-39 | | S-P Managed Care/ITG Transform MCOs Into Advocates Creative Contracting | Relevance | SP/W |
| 580 | SW0741559-80 | | Managed Care Memorandum/Proventil | Relevance | SP/W |
| 581 | WAR005587 7-81 | 5/5/00 | Letter from Tom Bliley (US House of Representatives Committee on Commerce) to Mr. Raman Kapur (Warrick) re: Pricing practices for Medicare pharmaceuticals | Relevance Hearsay | SP/W |
| 582 | WAR005587 5-6 | 10/18/99 | Letter from Tom Bliley (US House of Representatives Committee on Commerce) to Mr. Richard Kogan (Schering Plough) re: how Schering Plough calculates AWP for Albuterol sulfate | Relevance Hearsay | SP/W |
| 583 | WAR005587 1-4 | 7/19/99 | Letter from Tom Bliley (US House of Representatives Committee on Commerce) to Mr. Raman Kapur (Warrick) Re inquiry into establishing prices for the Medicare reimbursements | Relevance Hearsay | SP/W |
| 584 | WAR000258 1-82 | | Main Frame systems instructions for Reflections | Relevance | SP/W |
| 585 | WAR000251 6-17 | | Total Line Rebate Procedure | FRE 403 | SP/W |
| 586 | WAR000251 2-13 | | Bill Back rebate instructions | FRE 403 | SP/W |
| 587 | WAR000631 4-20 | 6/21/96 | Memo and attached minutes from L. Manfredi to Distribution re: Sales Directors Meeting June 17/18, 1996 | FRE 403 | SP/W |
| 588 | SPF0045734 -79 | 8/28/00 | Slide Show by Bruce Wallace re: Managed Care/Health Management | Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|----------------------|-----------------------------------|
| 589 | SW0739203-10 | | Audit Report No. 97-105, Schering Laboratories, Wholesaler Chargeback, Amerisource Corporation, Eden Prairie, Minnesota | FRE 403 | SP/W |
| 590 | SW0739077-81 | 2/2/00 | Letter from Frank J. DiLascia to Jim Finocchi re: Schering Plough offering to A&P Supermarket Service Corporation program for the year 2000 for Proventil | FRE 403 | SP/W |
| 591 | SW0739082-6 | 1/31/00 | Letter from Frank J. DiLascia to Barrett Moravec re Schering Plough offering to ABCO Markets, Inc. program for the year 2000 for Proventil | FRE 403 | SP/W |
| 592 | SW0739087-93 | 7/24/00 | Letter from Frank J. DiLascia to Dave Vucurevich re: Schering Plough offering to Albertson, Inc. program for the year 2000 for Proventil | FRE 403 | SP/W |
| 593 | SW0739094-98 | 7/24/00 | Letter from Frank J. DiLascia to Tony Mihelich re: Schering Plough offering to American Drug Stores, Inc. program for the year 2000 for Proventil | FRE 403 | SP/W |
| 594 | WAR0001301 | 10/25/99 | Top 20 Medicaid Products 3Q99 Filing | Relevance | SP/W |
| 595 | WAR0052485-502 | | Slideshow by Carolyn J. McElroy re: Special Report Marketing Practices and Rebate Issues: Are They on a Collision Course? | Relevance Hearsay | SP/W |
| 596 | SW0092384-418 | | March, 2000 Slideshow: Legal Issues Managed Care/ Health Management National Meeting | Relevance Hearsay | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|----------------------|--|---------------------------------|-----------------------------------|
| 597 | WCT014534 9-66 | 10/1/93 | Agreement between Warrick and Bi-Coastal Pharmaceuticals re: employment as sales broker | Relevance | SP/W |
| 598 | WCT014540 2-13 | 12/2/97 | Agreement between Cardinal Health and Warrick re: authorized distributor | FRE 403 | SP/W |
| 599 | WCT014542 6-30 | 3/1/00 | Executed copies of Total Line Rebate Agreement between Warrick and Eckerd | FRE 403 | SP/W |
| 600 | WAR001984 6-48 | | Warrick Rebates | FRE 403 | SP/W |
| 601 | SPW003914 5 | 9/21/95 | Letter from Jerome Sherman to Bill Folk re: price increase of Albuterol Sulfate | FRE 403 | SP/W |
| 602 | WAR003101 1-13 | 12/20/00 | Letter from Jesse Mensah to Bev Campbell re: Warrick Promotion Rebate | FRE 403 | SP/W |
| 603 | WAR003350 9 | 2/16/01 | Memo to Mark Ritchey from Jerome Sherman re: New Product Proposal – Oxaprozin Tablets | FRE 403 | SP/W |
| 604 | SPW003917 8-88 | 5/8/97 | Letter from Jerome Sherman to Bill Roth with attached Cardinal Health Generic Wholesale Service Agreement dated 3/1/97 | FRE 403 | SP/W |
| 605 | WAR000053 3-35 | 6/8/99; 1 1/30/99 | Memos to Samantha Vossenberg from Jerome Sherman re: Price Change Albuterol, USP Inhalation Aerosol | FRE 403 Lack of Foundation | SP/W |
| 606 | SPW004215 1 | 10/12/93 | Letter from Henry Weintraub to Beth Rader and Ed Edlestein re: price change for albuterol sulfate | FRE 403 | SP/W |
| 607 | SPW003887 9 | 11/22/95 | Memo from P. Simoradzki to C. Hagman re: price of Albuterol, USP Inhalation Aerosol | Relevance Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------|---|--|-----------------------|-----------------------------------|
| 608 | RGX 0001195-97 | | Harvey Weintraub Curriculum Vitae | Relevance | SP/W |
| 609 | RGX 0001208-17 | 12/90 | Generics – Generics Paper Managed Care by J. Audibeft (sp) | Relevance | SP/W |
| 610 | RGX 0001223 | 4/26/99 | Warrick Account Information Form re: price change to Albuterol Solution/Syrup | FRE 403 | SP/W |
| 611 | RGX 0001224 | 6/13/97 | Warrick Account Information Form re: rebate change to Albuterol Solution/Syrup | FRE 403 | SP/W |
| 612 | RGX 0001225-31 | 6/2/99; 3/16/99; 4/9/99; 4/22/99; 5/3/99; 7/2/99 | Warrick Account Information Forms re: price change or rebate change to Albuterol Solution/Syrup | FRE 403 | SP/W |
| 613 | RGX 0001232 | 2/23/95 | Letter from Henry Weintraub to Martha McNeil re: price increase for Albuterol Solution 0.5% 20 mL | FRE 403 | SP/W |
| 614 | RGX 0001233 | 9/22/95 | Letter from Henry Weintraub to Martha McNeil re: price increase for Albuterol Sulfate, USP Solution for Inhalation 0.5% 20 mL | FRE 403 | SP/W |
| 615 | WP0000276 9A | 6/25/96 | Warrick Promotion Agreement re: Albuterol Inhalers | FRE 403 | SP/W |
| 616 | WPX000167 4-75 | | Handwritten notes | Lack of Foundation | SP/W |
| 617 | WP0001232 2A-24A | 7/5/95 | Handwritten notes re: Albuterol Solution 20 mL pricing | Lack of Foundation | SP/W |
| 618 | WP0001233 0A | | Handwritten notes re: AWP | Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------|--|--|----------------------------------|-----------------------------------|
| 619 | WP0001262 9A-33A | 8/11/95; 9/7/95; 9/18/95; 9/29/95; 12/4/95 | Warrick Memos re: Albuterol pricing | FRE 403 Lack of Foundation | SP/W |
| 620 | WPX000767 8 | 12/11/95 | Memo from D. Reich to R. Bucko re: Warrick Inhaler Invoicing | FRE 403 | SP/W |
| 621 | RGX 0001522 | | Warrick Pharmaceuticals promotional piece for Albuterol | FRE 403 Lack of Foundation | SP/W |
| 622 | RGX 0001523 | 5/5/95 | Letter from Lee Edelstein to Harvey Weintraub re: sales results for Warrick Telemarketing Team | Relevance Hearsay | SP/W |
| 623 | RGX 0001524 | 6/7/95 | Letter from Henry Weintraub to Martha McNeill re: Cimetidine pricing | Relevance | SP/W |
| 624 | RGX 0001525-28 | 9/29/94 | Letter from Martha McNeill to R. Kapur re: Texas Medicaid reimbursement for Perphenazine | Relevance | SP/W |
| 625 | RGX 0001529-30 | 11/16/95 | Letter from Harvey Weintraub to Martha McNeill re: Perphenazine AWP price change | Relevance | SP/W |
| 626 | WWV00206 55-64 | 4/1/95 – 10/1/99 | Schering-Plough Generics Organization Charts | FRE 403 | SP/W |
| 627 | WWV00000 07 | 4/1/00 | Schering-Plough Generics Organization Chart | FRE 403 | SP/W |
| 628 | WWV00113 85-476 | | Warrick Pharmaceuticals Policy & Procedure | No objection | |
| 629 | WAR003514 9 | 8/11/95 | Memo from Harvey Weintraub to Joseph LaRosa re: price increase for Albuterol Solution for Inhalation 20 ml | FRE 403 Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------------------|--|--|------------------------------------|-----------------------------------|
| 630 | SPW003783 2; SWP003768 6 | 12/21/95 ; 2/23/95 | Letter from Harvey Weintraub to Beth Rader re: Albuterol pricing; Letter from Harvey Weintraub to Wyndy Jones re: Albuterol pricing | Relevance Lack of Foundation | SP/W |
| 631 | WAR000763 2-33 | 12/29/95 | Letter from Harvey Weintraub to Wyndy Jones re: Albuterol pricing | Relevance | SP/W |
| 632 | WAR000763 4-35 | 12/29/95 | Letter from Harvey Weintraub to Mukesh Mehta re: Albuterol pricing | Relevance | SP/W |
| 633 | WAR002408 6 | 2/23/95 | Letter from Harvey Weintraub to Beth Rader re: Albuterol pricing | FRE 403 | SP/W |
| 634 | WAR001601 1 | 3/28/96 | Memo to Douglas Batezal from Walt Gough re: Albuterol Price Change | Relevance | SP/W |
| 635 | WAR001669 0 | 4/16/96 | Memo to Anthony Tavolaro from Jerome Sherman re: Albuterol Price Change | Relevance | SP/W |
| 636 | WAR005454 5 | 6/11/93 | Memo from frank Musat to Gary Binder re: Warrick Albuterol Pricing | No objection | |
| 637 | WAR000612 0-21 | 7/23/93 | Memo from Harvey Weintraub to Mr. Zahn re: Warrick pricing | No objection | |
| 638 | SPW013818- 22 | 7/29/97; 9/21/95; 7/23/97; 9/21/95; 4/6/94 | Documents between Warrick and Walgreens re: Albuterol pricing and rebates; 9/1/95 Letter from Al Graf to John Ziebell | FRE 403 | SP/W |
| 639 | WAR002539 7 | 4/17/96 | Memo to John Ziebell from Al Graf re: Albuterol Price Change | FRE 403 | SP/W |
| 640 | SPW003858 5 | 2/99 | Addendum to 10/1/98 agreement between Schering Corporation and Scott & White Prescription Services | Relevance Incomplete | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|---|----------------------------------|-----------------------------------|
| 641 | SPW003858 6 | 2/99 | Exhibit A to Addendum to 10/1/98 agreement between Schering Corporation and Scott & White Prescription Services | Relevance Incomplete | SP/W |
| 642 | SPW003858 7 | 2/99 | Exhibit A-1 to Addendum to 10/1/98 agreement between Schering Corporation and Scott & White Prescription Services | Relevance Incomplete | SP/W |
| 643 | SPW003859 0 | | Document titled "Owens Healthcare Inc. Alternate Site Expiring 3/31/99 | FRE 403 | SP/W |
| 644 | SPW003859 1-2 | | Pharmacy Perspective Proventil/Albuterol | Lack of Foundation Incomplete | SP/W |
| 645 | SPW003859 3-94 | | Integration of Warrick Into Managed Care | Relevance | SP/W |
| 646 | SPW003859 5 | 4/23/96 | Memo from John Stockton to Betsy Chorpenning and David Reich re: Warrick Contract for Rx America | FRE 403 | SP/W |
| 647 | SPW003859 6-97 | 8/3/95 | Memo from Patti Niehaus to Cheryl Burrell re: PCA Health Plan of FL | FRE 403 | SP/W |
| 648 | SPW003851 4 | | Query SQL | Relevance | SP/W |
| 649 | SPW003851 5 | | MCR DB2 Data | Relevance Lack of Foundation | SP/W |
| 650 | SPW003851 6 | | Untitled Chart | Relevance | SP/W |
| 651 | | | SPW/AWP 2001-2004 Call Notes Sales Rep: Flynn, Mark (4 pages) | No objection | |
| 652 | WAR005451 9-28 | 5/20/93 | Memo from Richard Zahn to Raul Cesan re: Generic Albuterol Solution/Syrup Introduction | FRE 403 | SP/W |
| 653 | SW0584152- 78 | 6/22/99 | Memo from Jim Fitzpatrick to Raul Cesan, et al. re: ITG Business Review | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|-------------------------------|-----------------------------------|
| 654 | SW0582348-62 | | Handwritten notes of Gary Binder to Roch Dolineux with attachments re: AWP | Relevance | SP/W |
| 655 | SPF0023186 -93 | 6/21/00 | E-mail from Linda Zhou to Raul Cesan re: Medco with attachments | Relevance | SP/W |
| 656 | SPW003970 0-12 | | Profit Optimization of Current Portfolio Proventil Inhaler | Relevance | SP/W |
| 657 | SW0648205-6 | 7/24/98 | Memo from Richard Zahn to Raul Cesan re: Pacificare | Relevance | SP/W |
| 658 | SPW003914 6 | 9/21/95 | Letter from Walt Gough to Douglas Batezel re: Albuterol Price Increase | FRE 403 Lack of Foundation | SP/W |
| 659 | | | AWP/SPW 2001-2004 Call Notes Sales Rep.: Butler, James R. (3 pages) | Relevance | SP/W |
| 660 | | | SPW/AWP 2001-2004 Call Notes Sales Rep: Bishop, Gary (11 pages) | Relevance | SP/W |
| 661 | SPF0112246 -53 | 6/28/02 | E-mail from Ellen Schwarzberg to Anne Fields, et al. re: clarification of expense categories in EER with attached Spending Policy Quick Reference Guide | No objection | |
| 662 | SPW003922 8-29 | 12/1/01 | Letter from John Van Schaften to Martha McNeill re: Warrick Pharmaceuticals Pricing Update for the Month ending 11/30/01 | No objection | |
| 663 | SPW003923 0-32 | 11/30/01 | Letter from John Van Schaften to Martha McNeill re: Warrick Pharmaceuticals Pricing Update for the Period ending 11/16/01 to 11/30/01 | No objection | |
| 664 | SPW003923 3-36 | 2/2/00 | Contact Report | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|--|-------------------------------|-----------------------------------|
| 665 | SPW003923 7-39 | 11/29/01 | Affidavit of John Van Schaften In Opposition to Motions to Compel | No objection | |
| 666 | SPW003924 0 | | Letter from John Van Schaften to Martha McNeill re: Warrick Albuterol Inhalers pricing | Relevance | SP/W |
| 667 | SPW003924 1-46 | 2/12/97 | Memo from John Van Schaften to Robert Inserra re: McKesson auto-sub charges | FRE 403 | SP/W |
| 668 | SPW003924 7-50 | 7/9/01 | Contact Report | FRE 403 | SP/W |
| 669 | SPW003925 1 | 4/9/01 | Warrick Promotional Agreement | FRE 403 Lack of Foundation | SP/W |
| 670 | SPW003925 2-55 | 3/20/01 | Contact Report | FRE 403 | SP/W |
| 671 | SPW004061 9 | 6/15/99 | Memo to Martha Torres from Jerome Sherman re: Albuterol Price Change | FRE 403 | SP/W |
| 672 | SPW004062 0 | 6/15/99 | Memo to Martha Torres from Jerome Sherman re: Albuterol Price Change | FRE 403 | SP/W |
| 673 | SPW004062 1-50 | | Warrick Pharmaceuticals Discount Check Promotions | FRE 403 | SP/W |
| 674 | SPW004083 1 | 9/16/98 | E-mail from John Van Schaften to Jesse Mensah re: McKesson August '98 Autosub Invoice | Relevance | SP/W |
| 675 | SPW004083 2-37 | | Charts re Warrick Pharmaceuticals rebates | FRE 403 | SP/W |
| 676 | SPW003897 3 | 5/24/96 | Warrick Account Information Form Albuterol USP Inhalation Aerosol price change | Relevance | SP/W |
| 677 | SPW003897 4 | 6/4/96 | Warrick Account Information Form Albuterol USP Inhalation Aerosol price change | Relevance | SP/W |
| 678 | SPW003897 5 | 8/7/96 | Warrick Account Information Form Albuterol USP Inhalation Aerosol price change | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--|-------------------------|-----------------------------------|
| 679 | SPW003897 6 | 8/23/96 | Warrick Account Information Form Albuterol USP Inhalation Aerosol Auto Sub Program | Relevance | SP/W |
| 680 | SPW003897 7 | 10/14/96 | Warrick Account Information Form Albuterol USP Inhalation Aerosol | Relevance | SP/W |
| 681 | SPW003897 8 | 12/10/96 | Warrick Account Information Form Albuterol USP Inhalation Aerosol price change | Relevance | SP/W |
| 682 | SPW003897 9 | 4/4/97 | Warrick Account Information Form Albuterol USP Inhalation Aerosol price change | Relevance | SP/W |
| 683 | SPW003898 0 | 10/8/97 | Warrick Account Information Form Albuterol USP Inhalation Aerosol price change | Relevance | SP/W |
| 684 | SPW003898 8-89 | 7/31/97 | Letter from Lee Edelstein to Harvey Weintraub re: Warrick Telesales | Relevance Hearsay | SP/W |
| 685 | SPW003899 2-93 | 4/25/01 | Warrick Promotion Agreement | FRE 403 | SP/W |
| 686 | SPW003899 7-9076 | | Telemanagement Services, Inc. – Telephone Communication Skills Training – Module 1 | Relevance Hearsay | SP/W |
| 687 | SPW003965 8-70; SPW003965 6-57 | | Document titled “Schering\Warrick-Albuterol Inhaler-Action Plan” prepared by Steve Cooper and Mark Calabrese | Relevance | SP/W |
| 688 | SPW003967 1 | | Slide: Modeling Assumptions | Relevance Hearsay | SP/W |
| 689 | SPW003967 5-718 | 4/93 | Schering Laboratories Generic Market Strategic Plan | Relevance | SP/W |
| 690 | SPW003971 9 | | File Folder labeled “Generics – Keys In Generic Task Force Slides” | Relevance Incomplete | SP/W |
| 691 | SPW003972 0-65 | | Keys In Generic Task Force Slides | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|---------------------|--|---------------------------------|-----------------------------------|
| 692 | SPW003983 9-45 | | Untitled document | Relevance Lack of Foundation | SP/W |
| 693 | SPW003984 6-47 | | Pharmacy Perspective slide and MCO Perspective Slide | Relevance Lack of Foundation | SP/W |
| 694 | SPW003984 8-51 | | Proventil AP Launch Strategy and Transition Plan | Relevance | SP/W |
| 695 | SPW003985 2-54 | 10/2/95 | Memo from Carolyn Kocis to Lissa Colantouno re: RGPN Committed Contract Warrick | FRE 403 | SP/W |
| 696 | SPW003985 5-58 | 2/2/96 | Memo from Carolyn Kocis to Cheryl Leone re: RGPN-Warrick Albuterol Inhaler | FRE 403 | SP/W |
| 697 | SPW003986 5 | 6/10/93 | Memo from Richard Zahn to Raul Cesan re: Albuterol Solution/Syrup Warrick Update | Relevance | SP/W |
| 698 | SPW003954 5-46 | 7/96 | Warrick Customer Rebate Credit/Refund Checks form | Relevance | SP/W |
| 699 | SPW003956 3-64 | 9/20/95; 9/21/95 | Letter from Jerome Sherman to James Finocchi re: Abuterol price change with fax cover | FRE 403 | SP/W |
| 700 | SPW003958 0-81 | | Warrick Pharmaceutical Rebate Program | FRE 403 | SP/W |
| 701 | SW0002244 | 3/4/02 | March 4, 2002 Memo from Harvey Weintraub to Debbie Kane and Craig Masker | Relevance | SP/W |
| 702 | SW0301657- 72 | | Contract Admin. PPT. | Relevance | SP/W |
| 703 | SW0398766- 77 | | Schering-Plough Audit Report No. 2001-034 of Warrick | Relevance | SP/W |
| 704 | SW0398782- 94 | | Schering-Plough Audit Report Warrick Response | Relevance | SP/W |
| 705 | | | FENS 2464-0001019475 3-page Email chain re: Claims with Admin Fees based on AWP Gross Sales x 1.7% | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|--|-------------------------------|-----------------------------------|
| 706 | | | FENS 2464-0001034096 20-page Contracts and Pricing Rebate Administration Prelim. Assessment May 20, 1998 | Relevance | SP/W |
| 707 | | | February 2000 Schering-Plough updated version of the "Schering Sales Corporation Policy and Procedure Manual" | No objection | |
| 708 | | | February 2003 (last update) Schering Sales Corporation "Sales Policy and Procedures" manual | No objection | |
| 709 | SW0154713-77 | 4/00/96 | Schering-Plough Field Force of the Year 2000, a "how-to" manual | No objection | |
| 710 | SW0023391 4-15 | 6/11/02 | Warrick letter Michael Kennedy to Linda Panke at Medical Economics Co. re: pricing and shipping info | FRE 403 | SP/W |
| 711 | SP0012427-29 | 6/24/98 | Schering Corporate Data Sheet | Relevance | SP/W |
| 712 | SP0012430 | 5/29/98 | Warrick Corporate Data Sheet | Relevance | SP/W |
| 713 | RGX025585 5-76 | | November 2001 Getting Away from AWP: Changing Medicare and Medicaid Drug Reimbursement | Hearsay Lack of Foundation | SP/W |
| 714 | SP000939-49 | 10/15/92 | Schering-Plough e-mail from Carolyn Kocis re: Nominal Pricing Meeting draft Executive Summary and Minutes | Relevance | SP/W |
| 715 | RGX003509 2-94 | 5/1/00 | Warrick fax Harvey Weintraub to Richard Zahn enclosing Price Change Summary sheets re: Mylan and investigates spread | Relevance | SP/W |
| 716 | WAR006558 9-607; WAR006561 4-37; WAR006565 2-719 | | Various Schering/Warrick Pricing Updates | No objection | |
| 717 | WCT002234 9 | 9/29/95 | Warrick memo Harvey Weintraub to John Hoffman re: Price Increase – Warrick Albuterol Solution 20 mL | FRE 403 Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|--|-------------------|-----------------------------------|
| 718 | WCT013386 1-67 | 9/21/95 | Warrick memo Dave Reich to C. Hagman re: Price Change for Albuterol 20 mL | FRE 403 | SP/W |
| 719 | WCT003183 6 WCT002015 9 WCT013503 6 WCT000242 7 WCT006212 3 | | Albuterol Price Notices | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--------------------|-------------------|-----------------------------------|
| | WCT001209 3-96 WCT001292 3 WCT002015 8 WCT002219 7 WCT002224 8 WCT002225 1 WCT002229 4 WCT013336 3 WCT001273 3 WCT013453 6 WCT013460 8 WCT013442 9 WCT013454 8 WCT003378 5 WCT013445 8 WCT013453 2 WCT013442 1 WCT013460 2 WCT003378 2 WCT013442 0 WCT013443 5 WCT013452 8 WCT013460 1 WCT013468 3 | | | | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|-----|---|------|-------------|------------|---------------------------|
| | WCT013336 4-66 WCT001207 3 WCT002002 3 WAR002410 6 WCT013441 8 WCT013451 7 WCT013406 9 WCT000262 2 WCT001219 7 WCT001213 6 WCT013447 3 WCT013456 5 WCT000201 7 WCT000202 3 WCT013456 1 WCT000202 1 WCT013473 8 WCT013446 9 WCT000201 9 WCT008844 5 WAR001181 2 WCT003376 9 WCT014075 1 WCT008843 4 WCT002296 7 WAR003832 1 WCT002240 8 SW0173547 CT0033756 | | | | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|---|-----------------------|-----------------------------------|
| | WCT014557 0-72 WCT007308 2 WCT000181 6 WCT003356 3 WAR005317 3 WCT003355 5 WCT003353 8 WCT008845 4 WCT003349 8 WCT002242 6 WCT008986 1 WCT008983 5 WCT008875 1 WCT008882 1 WCT008979 4 WCT008978 4 WCT008994 2 WCT008872 1 | | | | |
| 720 | SPF0001325 5 | | Intron-A pricing and reimbursement | Hearsay Incomplete | SP/W |
| 721 | SPF0001169 5-96 | 7/7/01 | E-mails re: Intron Reimbursement Issues- Summary and Calculation of Medicare Reimbursement- Example | No objection | |
| 722 | SW0720309- 56 | 8/23/02 | Intron-A Oncology 2003 Marketing Plan | No objection | |
| 723 | SW0719241 | | Cost Analysis for Superficial Bladder Cancer | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------|-------------|--|---|-----------------------------------|
| 724 | SPF0001171 8-20 | 5/26/00 | E-mail Jack Gomm to Jorge Diaz re: DTIC Admin. Analysis for profitability, and reimbursement for Temodar vs. DTIC | No objection | |
| 725 | SPF0001196 9-70 | | Temodar Information Sheet – Off-Label and Reimbursement | Hearsay | SP/W |
| 726 | SPF0001197 1-80 | | PowerPoint Presentation of Temodar: Dispensing Reimbursement and Managed Care | Hearsay Lack of Foundation | SP/W |
| 727 | SPF0001169 1-94 | 7/19/02 | E-mail exchanges between Jorge Diaz, Karen Freeman, Robin Smith and Ray Ledford re: Medicare Reimbursement for Temodar | Relevance | SP/W |
| 728 | SW0639131-49 | | ITG Overview | Relevance Incomplete Lack of Foundation | SP/W |
| 729 | SPF0092059 -64 | 6/18/99 | E-mail James Fitzpatrick to Kathleen Hurtado re: draft ITG Business Review | Relevance Hearsay | SP/W |
| 730 | SW0024429 8-300 | | ITG organization chart of employees and the employees accounts | Relevance | SP/W |
| 731 | WCT014536 7-75 | 9/2/97 | Fax Peter Janis to Raman Kapur attaching draft TMS Business Review | Relevance | SP/W |
| 732 | WCT014606 1-76 | | TMS/Warrick Rebates, Fees, Check Requests and Agreements | FRE 403 | SP/W |
| 733 | WCT014597 7-94 | | TMS/Warrick Pharmacy Rebate Check/Invoice Audit, Invoices, Discount Check Promotion, Product Summary Reports and Check Request | FRE 403 | SP/W |
| 734 | | 11/14/94 | Warrick letter Harvey Weintraub to Lee Edelstein of TMS re: telemarketing and costs | Relevance | SP/W |
| 735 | WAR004158 3-96 | 9/12/02 | Fax Warrick Pharmaceutical Training for Access Worldwide manual for telemarketing | Relevance | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|---------------------------------|-----------------------------------|
| 736 | SW0041080-2 | | Email from Todd Grisco to Craig Granowitz re: CTC ad BIC data. Attached is 2001 CTC Free Drug (\$) with handwritten notes | Relevance Lack of Foundation | SP/W |
| 737 | SPF0000499-501 | | Email chain from Aracelia Vila to Kathy Zonca, Holly Wong, Donna Conroy re: Commitment to Care | Relevance | SP/W |
| 738 | SPF0001946 0-1 | | “Commitment to Care Program” Business Review Major Findings | Relevance | SP/W |
| 739 | SPF0002050 2-5 | | Email from Todd Grisco to Douglas Subers, Pilar Villegas, James Fitzpatrick re: 2001 CTC numbers and attaching documents 2001 CTC Free Drug (\$) and CTC Reimbursement Found 2001 Summary | Relevance | SP/W |
| 740 | SPF0002050 6-8 | | Email from Todd Grisco to James Fitzpatrick re: 2001 CTC Free Drug and attachment | FRE 403 | SP/W |
| 741 | SPF0001151 7-46 | | Email and attachment from Agnes DeOcampo to Jorge Diaz re: Possible addition of Intron Drug Replacement in Schering SOP | FRE 403 | SP/W |
| 742 | SPF0001150 6-16 | | Email and attachment re: Temo economics. Attachment is “Impact of Financial Burden on Prescribing Patterns” slideshow | FRE 403 | SP/W |
| 743 | SW0026577-96 | | Commitment to Care Charts (McKesson/HDS) | FRE 403 | SP/W |
| 744 | SW0036906-22 | | Memoranda from Kennedy Mohammed to Linda Hagman re: CTC Credit | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------------------|-----------------------------------|---|---------------------------------|-----------------------------------|
| 745 | SPF0171131-9 | | Email and attachments from Steven Petruccelli to Ray Ledford, Joan Chiaviello, Mark Mazo, Jane Detrie, Janet Gusmerotti, Ronald Taylor, Russell Hubbs, Vincent Lawler, Jeff Sherman, Jack Micali Chuck Pearson, Sheri Jepson, Jeffrey Pfister, Thomas Saenz, Mary Metheny, Thomas Lander, Joanne Steele, Scott Yokobosky, Gregory Meadows, Harry Durr re: CTC Overview and Flowcharts | FRE 403 | SP/W |
| 746 | FDB-AWP 04170 | 7/16/02 | Letter from Henry Weintraub to Kay Morgan re: Albuterol pricing | Relevance Lack of Foundation | SP/W |
| 747 | SP 0012851-54 | 6/4/93 | Memo from R.M. Loughlin to Attendees re: Albuterol launch | Relevance | SP/W |
| 748 | WP0000151 5A | 11/29/93 | Rx Product Introduction/Change Notice re: Albuterol Inhalation Aerosol- Warrick | Relevance | SP/W |
| 749 | WP0001723 0A-39A | 1/1/94 | Consulting Agreement between Schering Corporation and M&H Associates | Relevance | SP/W |
| 750 | WPX000770 6-07; WPX000770 9 | Undated ; 12/8/95; 11/16/95 | Undated filed folder titled "Greens" ; Rx Product Introduction/Change Notice re: Albuterol Inhalation Aerosol | FRE 403 | SP/W |
| 751 | WPX000767 6 | 12/6/95 | Memo from P. Sinoradzki to C. Hagman re Revised Price for Albuterol Sulfate, USP Inhalation Solution 0.05% 20 mL | FRE 403 | SP/W |
| 752 | WP 00017242A; WP 0001893 4A | 9/17/96; 5/29/01 | Caremark Prescription invoice for Albuterol; Merk-Medco Rx invoice for Albuterol | FRE 403 | SP/W |
| 753 | WP0001205 3A-84A | 10/96-10/97 | Warrick Pharmaceuticals Policy and Procedure | No objection | |
| 754 | AGQWP-012498-500 | 2/28/96 | Memo from D. Reich to L. Colantuano/R. Ecker re: Warrick Pricing Review | FRE 403 | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------------------|-------------|--|---------------------------------|-----------------------------------|
| 755 | SP 0013845 | 6/1/93 | Memo from Harvey Weintraub to Richard Zahn re: Warrick Albuterol-Retail Buying Groups | Relevance | SP/W |
| 756 | WP 0038221A-22A | 11/8/02 | Document titled "Lowest Price Calculation (Effective 11/8/02)" transmitted from H. Weintraub to R. Kapur, R. Gerardino and J. van Schaften | FRE 403 | SP/W |
| 757 | WP 0024172A-75A | 3/22/01 | Fax from Harvey Weintraub to Jerry Sherman and Walt Gough with attached Price Comparison Report for Effective Date 03/33/2001 | FRE 403 | SP/W |
| 758 | | 9/27/01 | Warrick Price File By NDC Desc. | FRE 403 | SP/W |
| 759 | WP0000280 9A-10A | 10/31/96 | Warrick Price File By Name | FRE 403 | SP/W |
| 760 | RGX 0173029-196 | | Company Policy & Procedure Manual For Field Sales Representatives | No objection | |
| 761 | RGX 0255855-76 | 11/01 | Getting Away from AWP: Changing Medicare and Medicaid Drug Reimbursement | Hearsay Lack of Foundation | SP/W |
| 762 | WPX000330 9-20 | | Rebate Agreement Between The Secretary of Health and Human Services and Warrick Pharmaceuticals Corporation | Relevance | SP/W |
| 763 | TX-D 7 W-012307; TX-D 7 W-012309-10 | 9/3/93 | Letter from Henry Weintraub to Beth Rader and Ed Edelstein re: new Albuterol package size | FRE 403 | SP/W |
| 764 | TX-D & W-012308; TX-D & W-12305 | 10/12/93 | Letter from Henry Weintraub to Beth Rader and Ed Edelstein re: Albuterol price change | FRE 403 | SP/W |
| 765 | WP0000177 5A | 8/26/94 | Letter from Angela Glauberzon to Sean O'Connell re: Albuterol in the Virginia generic substitution formulary | Relevance Hearsay | SP/W |
| 766 | WP0000162 9A | 12/30/95 | Letter from Phyllis Sinoradzki to Michael Neff, Chief, Medi-Cal Contracting Section re: Albuterol availability | Relevance Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------------|----------------------|--|------------------------------------|-----------------------------------|
| 767 | RGX 0056642 | 9/12/94 | Letter from Henry Weintraub to Beth Radar re: Perphenazine pricing | Relevance | SP/W |
| 768 | RGX 0056639; RGX 0056666 | 4/12/95; 11/16/95 | Letters from Henry Weintraub to Beth Radar re: Perphenazine pricing | Relevance | SP/W |
| 769 | RGX 0086536-44 | 1/31/02 | Warrick Price File By Name | FRE 403 | SP/W |
| 770 | WP0001212 8A | 9/21/95 | Letter from Jerome Sherman to Brian Slusser re: Albuterol Pricing | FRE 403 | SP/W |
| 771 | RGXA 0098615-23 | | Handwritten notes re: Albuterol pricing | Lack of Foundation | SP/W |
| 772 | WP0000481 5A-18A | 12/22/95 | Letter from Peter Kamins and Henry Weintraub to Michael LaBreque of Jack Eckard Corp. re: Proventil Chain Market Share Program | FRE 403 | SP/W |
| 773 | SP0004426; SP0004428 | 3/15/96 | Contract between Warrick and HealthPartners for Albuterol | No objection | SP/W |
| 774 | RGXA 0035102 | | Medicap Pharmacies, Inc. Generic Vendor Selection Criteria/Generic Product Selection Criteria | Relevance Hearsay Incomplete | SP/W |
| 775 | RGXA 0085152 | | Handwritten notes "Action Steps" | Relevance Lack of Foundation | SP/W |
| 776 | SP 0004773-77 | 1/20/97 | Letter to Paul Pelanek of Pharmaceutical Buyers, Inc. from Lissa Colantuono re: administration fees with attached price charts | Relevance | SP/W |
| 777 | RGX 0002271; RGX 0002310 | | PharmaGen promotional piece and pricing chart | Relevance Hearsay Incomplete | SP/W |
| 778 | WP 0023700A | 12/3/93 | Memo from Harvey Weintraub to Distribution re: HCFA - MAC Rulings | Relevance | SP/W |
| 779 | RGXA 0035098-102 | 6/8/95 | Letter from Janet Miller of Medicap Pharmacies, Inc. to Jerry Sherman | Relevance | SP/W |
| 780 | RGX 0178842 | | Potential Discussion Points of Interest to Eckerd's | Hearsay Incomplete | SP/W |
| 781 | SP 0002800 | | Warrick Pharmaceutical product chart | Hearsay Incomplete | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------------------------|------------------|---|----------------------|-----------------------------------|
| 782 | AGOWP-000202; WP0000137 2A | 7/8/99; 3/2/99 | Memo from Jerome Sherman to Martha Torres re: Albuterol price change; Warrick Account Information Form re price change for Albuterol | Relevance | SP/W |
| 783 | RGX 0179000 | | Preferred Rx Options – Program Features for Branded Pharmaceutical Suppliers | Hearsay Relevance | SP/W |
| 784 | RGX 0068132-33 | 10/19/98 | Memo from Harvey Weintraub to R. Kapur re: AWP Warrick ISMN Tablets and Memo from Jerry Sherman to Harvey Weintraub re: ISMN Market Information | Relevance | SP/W |
| 785 | RGX 0276183 | 10/26/98 | Memo from L. Manfredi to C. Hagman re: Isosobide Mononitrate Extended Release Tablets 60mg | Relevance | SP/W |
| 786 | WP 0024149A-67A | | Telemanagement Services, Inc. Telephone Communications Skills Training Module 2 for Pharmacy Department Representatives | Hearsay Relevance | SP/W |
| 787 | WP0001440 7A-08A | | Access Worldwide – Site Visit Issue | Lack of Foundation | SP/W |
| 788 | WP0001440 5A-06A | | Possible Issues | Hearsay Incomplete | SP/W |
| 789 | WP 0024115A; WP 0024114A; WP 0024156A | 6/25/01; 7/16/01 | Letter from Harvey Weintraub to Francine Kositsky re: Telemanagement Services Training Manual; Letter from Harvey Weintraub to Francine Kositsky re: insert (attached) to Warrick Sales Training Manual for Telemarketers | Relevance Incomplete | SP/W |
| 790 | WP 0024147A | 5/1/01 | Warrick Pharmaceuticals Discount Check Promotions | FRE 403 | SP/W |
| 791 | RGX 0016763 | 9/8/98 | Memo from R. Kapur to D. Malanga, et al. re: Price Reports to Third Parties; AWP, WAC, etc. | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------|--------------------|--|--|-----------------------------------|
| 792 | WPX000689 1 | 7/26/96 | Letter from Joseph E. Davis, State of Maryland DHMH, to Drug Manufacturers re: Albuterol pricing | Relevance Hearsay | SP/W |
| 793 | RGXA 0007659-61 | 7/2/98 (letter) | File folder titled "Arkansas DUR"; Handwritten note to Manfredi from Weintraub; Letter from Thelma Underwood, Arkansas Dept. of Human Services, to L. Manfredi | Relevance Hearsay Lack of Foundation | SP/W |
| 794 | WP0000083 8A-42A | 3/11/97 | Letter from Louis Manfredi to Martha McNeil re: Warrick Pharmaceuticals Product Line with attachments | Relevance | SP/W |
| 795 | WFL009443 0 | 3/11/97 | Letter from Louis Manfredi to Martha McNeil re: Warrick Pharmaceuticals Product Line with attachments | FRE 403 Lack of Foundation | SP/W |
| 796 | RGX 0190051-69 | | File folder titled "First Data bank Folder"; letter from Chris Bovard to Janice Brennan with attached Price Report | Hearsay FRE 403 | SP/W |
| 797 | RGX 0190087-88 | 12/98 | Letter from Chris Bovard to Valued Customer re: MDDB product line | Relevance Hearsay | SP/W |
| 798 | FDB-Florida 000468 | 4/8/02 | Letter from Janice Brennan to Marc Shirley re: Isosorbide Mononitrate | Relevance | SP/W |
| 799 | RGX 0190075-84 | | National Drug Data File Product Update Report Prepared By First DataBase | Hearsay FRE 403 | SP/W |
| 800 | RGX 0189706-07 | 7/16/99 | Letter from Lola Nannas of Red Book to Pharmaceutical Manufacturers re: product pricing | Hearsay Relevance | SP/W |
| 801 | RGXA 0085145 | 7/16/02 | Letter from Harvey Weintraub to Kay Morgan re: Albuterol pricing | Relevance | SP/W |
| 802 | RGX 0258420 | 9/6/02 | Memo from Janice Brennan to Harvey Weintraub re: Redbook – Missing Product Listings – Update | Relevance Lack of Foundation | SP/W |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------|-------------|--|-------------------------------|-----------------------------------|
| 803 | RGX 0258301-10 | 6/11/02 | Letter from B. Kennedy to Linda Panke re: Albuterol pricing with attached Pricing Service Listings | Relevance | SP/W |
| 804 | SPF0226510 -11 | 5/20/02 | E-mail from R. Kapur to Dan Valerio, et al. re: Proventil Solution Launch Mailings | Relevance | SP/W |
| 805 | SPF0129237 | 1/5/02 | Email from Janice Brennan to Romilda Heatter re: Warrick Pricing Letters for ME 04/30/02 | Relevance | SP/W |
| 806 | RGX 0219435 | 1/2/96 | AWP Package Pricing History for Albuterol from Analy\$ource | Hearsay Lack of Foundation | SP/W |
| 807 | | 3/27/06 | Notice of Deposition of Defendant Warrick Pharmaceuticals Corporation in State of Wisconsin v. Amgen | Relevance | SP/W |
| 808 | | 2/21/06 | Notice of Taking Depositions | Relevance | SP/W |
| 809 | RGX 0315084-141 | 8/12/99 | Letter to Thomas Bliley from Richard Zahn | No objection | |
| 810 | RGX 0154625-48 | 8/1/97 | Memorandum to Distribution from Linda Zhou re: Managed Care/ITG Reporting Package | Relevance | SP/W |
| 811 | WP0000000 65A-67A | 10/12/93 | Letter to Martha McNeil from Harvey Weintraub | FRE 403 | SP/W |
| 812 | | | 1998 Drug Topics Red Book (Excerpts) | Hearsay FRE 403 | SP/W |
| 813 | | | Printout from the National Pharmaceutical Council Website titled "About NPC" | Hearsay Relevance | SP/W |
| 814 | | 00/00/00 | Pharmaceutical Benefits Under State Medical Assistance Programs | Relevance Hearsay | SP/W |
| 815 | | 8/14/00 | Email to Harvey Weintraub from Dan Valerio re: Redbook Omissions Letter | FRE 403 | SP/W |
| 816 | | 12/11/97 | Memorandum to R. Cesan and R. Zahn from Linda Zhou re Pacificare Proposal | Relevance | SP/W |
| 817 | MDL-CEN000553 07-13 | 6/21/02 | Rebate Agreement Between Harvard Pilgrim and Johnson & Johnson | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---|-------------|--|-------------------|-----------------------------------|
| 818 | MDL-CEN000555 37-42 | 2/26/03 | Rebate Agreement Between Fallon Clinic and Centocor Inc. | No objection | |
| 819 | MDL-CEN000139 66; 13970; 14835; 14008; 13994; 14027; 13976-77 | 6/13/01 | Composite Exhibit of Price Increase Letters from Ron Krawczyk | No objection | |
| 820 | MDL-CEN000142 34; 13287; 14836; 14231; 14091 | 11/3/00 | Composite Exhibit of Price Increase Letters from Ron Krawczyk | No objection | |
| 821 | MDL-CEN000148 38; 13917-18 | 3/23/00 | Composite Exhibit of Price Increase Letters from Ron Krawczyk | No objection | |
| 822 | MDL-CEN000000 05; 7; 13; 13718 | 6/18/99 | Composite Exhibit of Price Increase Letters from Mike Ziskind & Ron Krawczyk | No objection | |
| 823 | WKH 01027-28 | 9/1/98 | Price List for Remicade | No objection | |
| 824 | MDL-CEN000827 02-03 | 3/23/00 | Interoffice Memorandum from Tom Weiss re: Remicade 4.9% Price Increase | No objection | |
| 825 | MDL-CEN000126 67 | | Remicade Price Increase History | No objection | |
| 826 | MDL-JJ00000108-110 | 7/8/02 | Email from Patricia Molino re: AWP Discrepancy Questions | No objection | |
| 827 | MDL-JJ00000095-96 | 6/20/02 | Email from William Baxter to Diane Ortiz re: AWP Analysis | No objection | |
| 828 | MDL-CEN001036 88-90 | 9/22/02 | Email from Seth Fischer re: AWP Reporting Issue: an Overview | No objection | |
| 829 | MDL-OBI00007620 | 7/11/01 | Email from Timothy Traver to Cathleen Dooley re: AWP vs. Acquisition Cost | No objection | |
| 830 | | 12/03/03 | Amended Notice of Rule 30(B)(6) Depositions | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|--|-------------------|-----------------------------------|
| 831 | MDL-CEN000139 65; 13969; 14002; 14004; 14008 | 6/13/01 | Composite Exhibit of Price Increase from Ron Krawczyk | No objection | |
| 832 | MDL-CEN000304 66-67 | 3/16/98 | Interoffice Memorandum from Matthew Carpenter to J. McHugh & J. Kerrigan re: Average Acquisition Price vs. Average Acquisition Price | No objection | |
| 833 | MDL-CEN000055 08-10 | 2/21/02 | Email from Michael Ziskind to Rick Anderson re: AWP Pricing Per My Voice Mail | No objection | |
| 834 | MDL-CEN000559 24-88 | | Centocor Records Retention Schedule – Version 1.0 | No objection | |
| 835 | MDL-CEN000271 34-52 | 1/22/03 | Email from John Hoffman to Tom Weiss attaching PBM SPP Strategy | No objection | |
| 836 | MDL-CEN000145 97-98 | 00/00/01 | Remicade RA 2001 Tactical Budget | No objection | |
| 837 | | 8/2/05 | Notice of 30(B)(6) Deposition of Defendant Centocor Concerning Dealings With Private Insurers and Payors | No objection | |
| 838 | MDL-CEN000247 08-10 | 8/20/99 | Cost Comparison of Anti-TNF Agents in Rheumatoid Arthritis Patients Receiving Methotrexate for Plan & Group Members | No objection | |
| 839 | MDL-CEN000715 90-92 | 2/22/02 | Email from Tony Vernon to Michael Ziskind re: AWP Reporting Issue: An overview | No objection | |
| 840 | MDL-CEN000305 94-610 | 7/1/02 | Email from Cheryl Kramer re: Direction to the Field Sales Organization Re: Flat Infusion Advocacy | No objection | |
| 841 | MDL-CEN000007 11-718 | 9/24/01 | Rebate Agreement – The Regence Group | No objection | |
| 842 | MDL-CEN000679 57-58 | 5/22/01 | Interoffice Correspondence to Bob Savage from Dave Holveck re: Confidential – Proposed Remicade Price Increase | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------------------|-------------|---|--|-----------------------------------|
| 843 | BMS/AWP/0 01483100-21 | 2/4/03 | Email from Marsha Peterson to Doug Storer re: POA Powerpoint | No objection | |
| 844 | BMS/AWP/0 01487357-62 | | Smart Practices Require Best Practices from the OTN Website | No objection | |
| 845 | BMS/AWP/0 01487883- 5001 | 3/24/03 | Memorandum from Marsha Peterson to Gena Cook re: Western Region Summary -April 2003 | No objection | |
| 846 | BMS/AWP/0 01484077- 101 | 6/6/03 | Email from Jim Smith to Marsha Peterson, Joseph Wornson & Gena Cook re: MSHO BID | No objection | |
| 847 | BMS/AWP/0 01487993-95 | 8/19/02 | Email from Julie Trueblood re: Gabor Kovacs MD/#200600/Laguna Beach/CA/MOASC | No objection | |
| 848 | BMS/AWP/0 01484591- 613 | 2/26/03 | Email from Gena Cook to Marsha Peterson & Todd Little re: OHOA with Drug Purchases | No objection | |
| 849 | Roger Belltje 03291-304 | 8/22/95 | RedBook Product Listing Verification | Lack of foundation Hearsay Relevance as to drugs not in the case | Track 1 Defendants |
| 850 | Roger Belltje 03228-242 | 9/26/96 | RedBook Product Listing Verification | Lack of foundation Hearsay Relevance as to drugs not in the case | Track 1 Defendants |
| 851 | AWP-PIPE 00002- 000037 | 11/1/05 | Pipefitters Local 537 January 1, 2006 Renewal | No objection | |
| 852 | AWP-PIPE 000038- 000065 | 11/1/00 | Pipefitters Local 537 January 1, 2001 Renewal | No objection | |
| 853 | AWP-PIPE 000066- 000093 | 11/9/98 | BCBS Pipefitters Local 537 January 1, 1999 Renewal | No objection | |
| 854 | AWP-PIPE 000094- 000109 | 9/24/99 | Administrative Service Account Agreement | No objection | |
| 855 | AWP-PIPE 000144A- 000159 | 11/1/03 | BCBS Pipefitters Local 537 January 1, 2004 Renewal | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------------|-------------|--|-------------------|-----------------------------------|
| 856 | AWP-PIPE 000160- 000188 | 10/22/02 | Pipefitters Local 537 January 1, 2003 Renewal | No objection | |
| 857 | AWP-PIPE 000189- 000223 | 11/2/01 | Pipefitters Local 537 January 1, 2002 Renewal | No objection | |
| 858 | AWP-PIPE 000255- 000283 | 10/25/99 | Pipefitters Local 537 January 1, 2000 Renewal | No objection | |
| 859 | AWP-PIPE 000316- 000342 | 2000 | Pipefitters Union Local 537 Health & Welfare Plan Benefits Design | No objection | |
| 860 | AWP-PIPE 000389- 000483 | | Benefit Description, Major Medical | No objection | |
| 861 | AWP-PIPE 000518- 000522 | 3/31/03 | Wall Street Journal Article “Hired to Cut Costs Firms Find Profits in Generic Drugs” | No objection | |
| 862 | AWP-PIPE 000523- 000556 | 1/1/03 | Express Scripts, Inc. Managed Prescription Drug Program Agreement | Relevance | Track 1 Defendants |
| 863 | AWP-PIPE 000599- 000607 | 12/04 | Select Pages of Redbook December 2004 Update | Hearsay | Track 1 Defendants |
| 864 | AWP-PIPE 000609- 000617 | 7/9/91 | Account Agreement Entered Into with BCBS MA | No objection | |
| 865 | AWP-PIPE 000618- 000625 | 9/8/92 | Account Agreement between Blue Cross Blue Shield of Massachusetts and Pipefitters Local | No objection | |
| 866 | AWP-PIPE 000661- 000676 | 11/30/99 | Administrative Services Account Agreement | No objection | |
| 867 | AWP-PIPE 000680- 000766 | 7/1/98 | Master Medical Benefit Description | No objection | |
| 868 | AWP-PIPE 000792- 000833 | - | Master Medical Benefit Description | No objection | |
| 869 | AWP-PIPE 000834- 000920 | 1/1/04 | Benefit Description Master Medical | No objection | |
| 870 | AWP-PIPE 000921- 001008 | | Pipefitters Local Union 537 Health & Welfare Plan Benefits Description | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|----------------------|-------------|---|-------------------|-----------------------------------|
| 871 | P 001294-1417 | 2/00/00 | United Food and Commercial Workers Unions and Employers Midwest Health Benefits Plan | No objection | |
| 872 | | 11/1/99 | Blue Cross Blue Shield of Illinois – Network Administration Agreement | No objection | |
| 873 | BCBSMA-AWP-00012-27 | 2/7/04 | Analysis of CMS Average Wholesale Price Reform – Reimbursement for Part B Drugs | No objection | |
| 874 | BCBSMA-AWP-000124-53 | 7/26/99 | Memo Ellen Thompson, Provider Reimbursement, to Ann Meneghetti, Medical Affairs, re: BCBSMA Reimbursement Policy Physician Dispensed RX | No objection | |
| 875 | BCBSMA-AWP-10002-05 | 1/00/02 | POS Outcomes Newsletter – Injectables: Don’t Get Stuck without a Plan for 2002 | Hearsay | Track 1 Defendants |
| 876 | BCBSMA-AWP-10569-74 | | Project Organizational Structure, Team Composition and Responsibilities | No objection | |
| 877 | BCBSMA-AWP-10586-91 | | Specialty Pharmacy Overview of RFP Response | No objection | |
| 878 | BCBSMA-AWP-10592-604 | | Specialty Pharmacy Overview | No objection | |
| 879 | BCBSMA-AWP-10605-08 | | PFSW Steering Committee Meeting- BC65 Drug Change Impact | No objection | |
| 880 | BCBSMA-AWP-10609-10 | 4/26/04 | Provider Financial Strategy Workgroup (PFSW) | No objection | |
| 881 | BCBSMA-AWP-11599-609 | 12/15/04 | Analysis of CMS Average Wholesale Price Reform – Reimbursement for Part B Drugs | No objection | |
| 882 | BCBSMA-AWP-11610 | 4/19/04 | Email Mike Mulrey to Deb Devaux, Steven Fox, John Killion and Jan Cook re: Impact of CMS Change in Drug Reimbursement | Hearsay | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------|-------------|---|-------------------|-------------------------------|
| 883 | BCBSMA-AWP-11611-12 | 3/22/04 | Email re: Blue Cross Fee Schedule | Hearsay | Track 1 Defendants |
| 884 | BCBSMA-AWP-11613-31 | 1/00/04 | Email Jan Cook to Peter Goldbach, Barry Zallen and John Fallon re: BC65 Drug Change Impact with attached analysis | Hearsay | Track 1 Defendants |
| 885 | BCBSMA-AWP-12120-46 | | BCBSMA Organizational Charts | No objection | |
| 886 | BCBSMA-AWP-12501 | 7/11/05 | Provider Financial Strategy Workgroup (PFSW) | No objection | |
| 887 | BCBSMA-AWP-12507 | 6/02/03 | Email Deborah Munro to John Killion re: Revised Saving Projections | Hearsay | Track 1 Defendants |
| 888 | BCBSMA-AWP-12508-09 | | Chart – BCBSMA '02 Spend @ Caremark by Drug Name w/extended AWP and Savings Projection based on Offer | No objection | |
| 889 | BCBSMA-AWP-12522-24 | 9/2/03 | Email Laura Liscio to Heather Cooke and John Killion re: AAHP Alert: AAHP Medicare Update #03-43a – CMS Published Proposed Rule To Pay Appropriately For Medicare-Covered Drugs | No objection | |
| 890 | BCBSMA-AWP-12525-50 | 8/20/03 | Federal Register, Department of Health and Human Services, Centers for Medicare and Medicaid Services- 42 CFR Part 405 Medicare Program; Payment Reform for Part B Drugs; Proposed Rule | No objection | |
| 891 | BCBSMA-AWP-12556-57 | 6/2/04 | Email Janis Pochini to Laura Liscio, Heather Cooke and John Killion re: Final Discounts | Hearsay | Track 1 Defendants |
| 892 | BCBSMA-AWP-12558 | 3/26/04 | Email Janis Pochini to John Killion and Laura Liscio re: Confidential Update | Hearsay | Track 1 Defendants |
| 893 | BCBSMA-AWP-12568 | 6/17/03 | Email Timothy Fitzgibbons to John Killion, Kim Olson, Annmarie Poopor and Rina Vertes re: Specialty Drug Update | Hearsay | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|----------------------------|-------------|--|--|-----------------------------------|
| 894 | BCBSMA-AWP-12576 | 2/7/05 | Email John Killion to Jan Cook and Holly Grinnell re: AWP Drug Analysis | No objection | |
| 895 | BCBSMA-AWP-12577-87 | 12/15/04 | Analysis of CMS Average Wholesale Price Reform – Reimbursement for Part B Drugs | No objection | |
| 896 | BCBSMA-AWP-12611-12 | 4/10/05 | Interoffice Memo Jan Cook to John Fallon, Deb Devaux and John Killion re: 4/6/05 Meeting with Massachusetts Society of Oncology (MSCO) | No objection | |
| 897 | BCBSMA-AWP-12960-3001 | 7/00/00 | BCBSMA, Inc. Indemnity Product Ancillary Professional Group Agreement | Hearsay Relevance | Track 1 Defendants |
| 898 | BCBSMA-AWP-13013-14 | 3/4/04 | Email Jan Cook to others re: Follow up to 2/23/02 Masco meeting | Hearsay | Track 1 Defendants |
| 899 | BCBSMA-AWP-13028-38 | 7/11/05 | 2005 Hospital Contracting Plan, PFSW | Illegible (BCBSMA-AWP-13034) | Track 1 Defendants |
| 900 | BCBSMA-AWP-13100-10 | 11/9/05 | BCBSMA Outpatient Fee Schedule Update Project | Relevance | Track 1 Defendants |
| 901 | BCBSMA-AWP-17052-54 | | Website ReimbursementCodes.com - Features and Benefits, New Feature- Medicare Part B vs. Part D Prescription Drug | Hearsay Incomplete | Track 1 Defendants |
| 902 | | 1/00/99 | BCBSMA HMO Blue Products Group Primary Care Physician Agreement | No objection | |
| 903 | | 9/00/00 | BCBSMA HMO Blue Product Group Primary Care Physician Agreement | Hearsay Relevance | Track 1 Defendants |
| 904 | | 11/00/02 | BCBSMA HMO Blue Product Group Primary Care Physician Agreement | Hearsay Relevance | Track 1 Defendants |
| 905 | GSK-MDL-KY04 000344-437 | 2/6/95 | Letter to Charles Wakerly from Timothy Proctor | Relevance Hearsay FRE 403 see Track 1 defendants' <u>in</u> limine motion | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--|-------------|---|--|-------------------------------|
| 906 | GSK-MDL-ZN02-101584-85 | 2/4/95 | Letter to Adriann Carter from Ursula Bartels re: Promotional Complaint | Relevance Hearsay FRE 403 see Track 1 defendants' <u>in limine</u> motion | Track 1 Defendants |
| 907 | GSK-MDL-KY04 000540-42; GSK-MDL-KY01 005532-42 | 2/22/95 | Letter to Timothy Proctor from Ursula Bartels | Relevance Hearsay FRE 403 see Track 1 defendants' <u>in limine</u> motion | Track 1 Defendants |
| 908 | GSK-MDL-KY03 000194-227 | 4/25/95 | Letter to Ursula Bartels from Adrianna Carter | Relevance Hearsay FRE 403 see Track 1 defendants' <u>in limine</u> motion | Track 1 Defendants |
| 909 | | | Blank | | |
| 910 | | 3/14/02 | Testimony of Thomas A. Scully, Administrator of Centers for Medicare & Medicaid Services, on Reimbursement & Access to Prescription Drugs under Medicare Part B, Senate Finance Committee, Subcommittee on Health | No objection | |
| 911 | | 4/00/03 | OIG Compliance Program Guidance for Pharmaceutical Manufacturers | Relevance | Track 1 Defendants |
| 912 | | 12/15/05 | Declaration of Raymond S. Hartman in Support of Plaintiffs' Claim of Liability and Calculation of Damages | Daubert Hearsay | Track 1 Defendants |
| 913 | | 12/6/01 | Sentencing Memorandum of the United States. <i>United States v. TAP Pharmaceutical Products, Inc.</i> , No. CR-01-10354-WGY (D. Mass. Dec. 6, 2001) | Relevance FRE 403 | AstraZeneca |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|--------------------|-------------|---|--|-----------------------------------|
| 914 | | 12/6/01 | <i>United States v. TAP Pharmaceutical Products, Inc., No. CR-01-10354-WGY (D. Mass. Dec. 6, 2001) – Disposition</i> | Relevance FRE 403 | AstraZeneca |
| 915 | TAP 5030224-458 | | Document titled “Big Mac Attack – Coach’s Playbook” | Hearsay FRE 403 Authentication | AstraZeneca |
| 916 | | 9/28/00 | Letter from the House of Representative Committee on Ways and Means, Subcommittee on Health, to President of the Pharmaceutical Research and Manufacturers of America | No objection | |
| 917 | | 10/31/00 | Letter from Congressman Stark to Commissioner of the Food and Drug Administration | No objection | |
| 918 | | 12/6/00 | Letter from Congressman Stark to Chief Counsel to the HHS Inspector General dated December 6, 2000; and Letter to Nancy-Ann Min DeParle from Thomas Bliley | No objection | |
| 919 | | 6/20/03 | Department of Justice Press Release “AstraZeneca Pharmaceuticals LP Pleads Guilty to Healthcare Crime: Company Agrees to Pay \$355 Million to Settle Charges” | Relevance FRE 403 | AstraZeneca |
| 920 | | 1/23/01 | Department of Justice Press Release “Bayer to Pay \$14 Million to Settle Claims for Causing Providers to Submit Fraudulent Claims to 45 State Medicaid Programs” | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|---|-----------------------------------|
| 921 | AM0038593-628 | | Aranesp Playbook Pricing & Contracting | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 922 | AM0994157-58 | 12/13/02 | Email from Mike Charles re: Important Ortho Competitive Information | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 923 | AM0933042 | 4/8/02 | Email from Amy Oliver re: Procrit Patient Access Program | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 924 | AM0079358 9-98 | 9/17/04 | Ortho Contract Update | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 925 | AM0016337 6-79 | 00/00/04 | Analysis by Amgen of the Updated Procrit Physician Office Contract | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 926 | AM0097610 6-07 | 1/9/04 | Email from Amy Oliver to Mike Charles re: Economic Analysis Workshop | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|--|---|-----------------------------------|
| 927 | AM0097610 8-16 | 7/1/03 | Draft Rebate Agreement | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 928 | AM0976123- 24 | | Hospital Economic Analysis | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 929 | AM0097611 7-18 | | Physician Office Economic Analysis | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 930 | AM0097611 9-20 | | Physician Office Economic Analysis | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 931 | AM0097612 1-22 | | Hospital Economic Analysis | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 932 | AM0018037 5-97 | | Updated Procrit – Physician Office Contract | Hearsay Relevance FRE 403 Not properly authenticated/ lacks proper foundation | J&J |
| 933 | | | Table 1A: Exemplar Defendant Drug List | Daubert | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------------------------|-------------|---|--|-----------------------------------|
| 934 | | | Distribution of Supplementary Health Insurance for the Medicare Population, 1996 Fee-for-Service Enrollees | Hearsay Authentication | Track 1 Defendants |
| 935 | BMSAWP/0 011214; BMSAWP/0 011221 | 9/6/1995 | Etopophos Launch Plan | Authenticity, incomplete document; also duplicative of PX 208; relevance, Plan was not adopted | BMS |
| 936 | BMS/AWP/0 00157426 | | Taxane Economics | Authenticity Incomplete document No foundation | BMS |
| 937 | BMS/AWP/0 00157428 | | Weekly Taxol Administration 80 mg/m2 | Authenticity Incomplete document No foundation | BMS |
| 938 | AZ0037018-19 | 3/22/95 | Memo from Oncology Specialty Marketing Team to Specialty Case Representatives re: New Case Quantity Discount | No objection | |
| 939 | FDB-AWP 04045 | 2/28/00 | Mailgram from Chris Bovard to Dear Customer | Relevance FRE 403 | SP/W |
| 940 | MDL-CEN000040 25 | 11/7/00 | Letter from Kelly Petrison to Mike Ziskind | Hearsay | J&J |
| 941 | BMSAWP/0 011250 | 10/3/93 | Letter from Denise M. Kaszuba to Mr. Edelstein | No objection | |
| 942 | | | Page 19 of a Banc of America Securities report re "Health Care Technology and Distribution" | Incomplete document Hearsay | Track 1 Defendants |
| 943 | | 7/2003 | Pages 2-5 of a Dyckman & Associates, LLC report titled "Health Plan Payment for Physician-Administered Drugs" | Incomplete document Hearsay | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-----------------------|--------------|---|---|-------------------------------|
| 944 | BMS/AWP/0 00100778 | | Document titled "Average Wholesale Price (AWP)" | No objection | BMS |
| 945 | BMS/AWP/0 00125509 | 2000 | Slide: "Average Whole Price (AWP)" | No foundation Hearsay Not a BMS document (part of an AdvancePCS presentation) | BMS |
| 946 | BMS/AWP/0 00101009-10 | | Slides: "How Drugs are Reimbursed" | No objection | BMS |
| 947 | BMS/AWP/0 00192749 | | Slide: "Variations on AWP or WLP" | No objection | BMS |
| 948 | | | Chart: "The Major PMSs All Use The AWP Benchmark In Their Contracts with Health Plan Clients" (7 pages) | Relevance PBM conduct not at issue Hearsay Daubert | Track 1 Defendants |
| 949 | | | Chart: "The Major PBMs All Use The AWP Benchmark In Their Contracts with Retail Pharmacies" (5 pages) | Relevance PBM conduct not at issue Hearsay Daubert | Track 1 Defendants |
| 950 | CVH 000028-31 | 5/10/04 | Document titled "Coventry Health Care National Retail Pharmacy Agreements" | Hearsay Relevance FRE 403 | Track 1 Defendants |
| 951 | BMS/AWP/0 00125508-15 | 2000 | Presentation by Todd Guinn "Drug Pricing" | Lack of foundation Hearsay Not a BMS document (AdvancePCS presentation) Relevance Does not relate to drugs at issue | BMS |
| 952 | | January 2003 | California HealthCare Foundation report: "Navigating the Pharmacy Benefits Marketplace" | Hearsay Relevance | BMS |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|-------------------|-------------|---|--|-----------------------------------|
| 953 | SMWMASS 001240-47 | | Sheet Metal Workers' National Health Fund payment records for Paraplatin | Relevance | Track 1 Defendants |
| 954 | SMWMASS 000605 | | Sheet Metal Workers' National Health Fund payment records for Cytoxan and Rubex | Relevance | Track 1 Defendants |
| 955 | SMWMASS 000092-96 | | Sheet Metal Workers' National Health Fund payment records for Procrit | Relevance | Track 1 Defendants |
| 956 | SMWMASS 001174-76 | | Sheet Metal Workers' National Health Fund payment records for Zoladex | No objection | |
| 957 | SMWMASS 000576-80 | | Sheet Metal Workers' National Health Fund payment records for Albuterol | Relevance | Track 1 Defendants |
| 958 | MDLW 25203-09 | 4/21/99 | Memo from Tim Callahan to Dariush Ashraft, et al. re: Pricing Issues | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 959 | PH 025785-94 | | Strategic Presentation on Average Wholesale Price (AWP) | Relevance Hearsay FRE 403; <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 960 | MDLW 05457-77 | | PowerPoint: Pricing & Reimbursement Key Strategies for Success | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 961 | MDLW 12564 | 2/24/97 | Memo from Tim Callahan to Mike Casey re INFeD Price Strategy | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 962 | FJ-MDL 005687-89 | 3/30/95 | Memo to Paul Kersten from David Klaum re March 1995 Monthly Report | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|---|--|-------------------------------|
| 963 | | 4/14/03 | Complaint for Injunctive Relief, Damages and Other Relief, <i>Dey, L.P. v. First DataBank, Inc., et al.</i> , No. 26-21019, (Sup. Ct. Napa County, CA.) | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 964 | IAWP00852 8-29 | 2/21/97 | Memo from John Frande and Keith Bridges re Reimbursement on Immunex products for AOR analysis | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 965 | IAWP01296 0-61 | | Health Care Policy Fast Facts What Happens When We Announce A Price Change For One of Our Products | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 966 | ABAWP 008988-93 | 11/92 | Reimbursement Alert | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 967 | ABAWP 012058-67 | 4/96 | Business to Business A quarterly newsletter from Centeon's Corporate Accounts and Sales Operation | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 968 | | 10/2/06 | Addendum Attachment A: Damages Summary and Backup – Declaration of Raymond S. Hartman: AWP Litigation Addendum to Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |
| 969 | | 10/2/06 | Attachment E – Declaration of Raymond S. Hartman: AWP Litigation In Support of Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |
| 970 | | 10/2/06 | Attachment G: Calculation of Spreads – Declaration of Raymond S. Hartman: AWP Litigation In Support of Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|---------------------|-------------|--|--|-------------------------------|
| 971 | | 10/2/06 | Attachment H – Declaration of Raymond S. Hartman: AWP Litigation In Support of Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |
| 972 | | 10/2/06 | Attachment I – Declaration of Raymond S. Hartman: AWP Litigation In Support of Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |
| 973 | | 10/2/06 | Attachment J: Damage Summary and Backup – Declaration of Raymond S. Hartman: AWP Litigation In Support of Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |
| 974 | | 10/2/06 | Attachment L: Additional Spread and Damages Calculation Notes and Assumptions For the October 2, 2006 Revisions – Declaration of Raymond S. Hartman: AWP Litigation In Support of Liability and Calculation of Damages | Daubert Relevance Hearsay | Track 1 Defendants |
| 975 | BAX MDL 0012778 | 6/11/96 | Memo from Hyle A. Bush to Pete O'Malley re: AWP/WAC | Relevance Hearsay FRE 403 <i>see Track 1 in limine motion</i> | Track 1 Defendants |
| 976 | MDL-OBI0006082 3-58 | | Presentation: 1999 Rebate Recommendations | No objection | |
| 977 | MDL-OBI0000100 1-2 | 3/23/97 | E-mail from Cathy Dooley to Christine McConnell re: Medicare Drug Payment | No objection | |
| 978 | MDL-OBI0000283 7 | 1/6/00 | Memo from Elaine Kling re: "Urgent – Price Change Notification" | No objection | |
| 979 | MDL-OBI0006102 5-6 | 2/19/97 | Memo from C. Dooley to S. Welden re: Medicare AWP Drug Reimbursement Proposal | No objection | |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|-------------------|------------------|-------------|--|--|-----------------------------------|
| 980 | | 7/27/04 | Responses of Schering-Plough Corporation to Plaintiffs' Interrogatories to the Fast Track Defendants | No objection | |
| 981 | RRPTOWJ | | Centcor, Inc. Remicade Sales Rotation at RA Launch Remicade v. Enbrel - Remicade Masters Sales Aid Site of Care/Reimbursement Issues [DVD] | Relevance Hearsay Not properly authenticated/ lacks proper foundation | J&J |
| 982 | | 8/5/02 | Presentation – “Procrit Contracting: Modeling Provider Economics” | No objection | |
| 982A ¹ | AZ0554945-60 | 3/26/03 | AstraZeneca Contracting - Steven Pitts, Contracting Director – Phoenix Team meeting | Late disclosure | AstraZeneca |
| 982B | AZ0463307 | 4/9/03 | Email from John Freeberry to David Brennan re: Current Pricing Issues | Late disclosure | AstraZeneca |
| 982C | AZ0048992-9023 | 1/15/91 | 1991 Zoladex Promotional Plan by J. R. Hildreth & C.M. Cook | Late disclosure | AstraZeneca |
| 982D | AZ0008783-84 | 6/21/94 | Internal Memorandum from Michael Tilton re: Zoladex | Late disclosure | AstraZeneca |
| 982E | AZ0037020-21 | | Draft Advertisement for Zoladex | Late disclosure | AstraZeneca |
| 982F | AZ008092-119 | 00/00/92 | Medical/Marketing Operating Plan 1992 | Late disclosure | AstraZeneca |
| 982G | AZ0048961-91 | 1994 | Zoladex Prostate Cancer 1994 Operational Plan | Late disclosure | AstraZeneca |
| 982H | AZ0009978-91 | 1995 | Zoladex Prostate Cancer 1995 Operational Plan | Late disclosure | AstraZeneca |
| 982I | AZ0004273-84 | 1997 | Advanced Prostate Cancer 1997 Operational Plan for Zoladex 3.6mg and 10.8mg and Casodex | Late disclosure Relevance as to Casodex | AstraZeneca |

¹ On October 9, 2006, Plaintiffs' filed "amended disclosures" including Exhibits 983-1008. Track 1 Defendants and Plaintiffs have conferred regarding the overlap in exhibit numbers caused by these additional exhibits and Plaintiffs have agreed to re-number the exhibits 982A-982Y.

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|--|-----------------------------------|
| 982J | AZ0043795-806 | 9/16/97 | Draft Zoladex Gyn/Breast Cancer 1997 Operational Plan | Late disclosure | AstraZeneca |
| 982K | AZ0033814-40 | 10/1/97 | 1998 Operational Plan – Casodex & Zoladex – October 1, 1997 | Late disclosure Relevance as to Casodex | AstraZeneca |
| 982L | AZ0001598-603 | 1998 | Prostate Cancer 1998 Operational Plan for Casodex & Zoladex with Handwritten Notes | Late disclosure Relevance as to Casodex | AstraZeneca |
| 982M | AZ0427138-783 | 1999 | 1999 Operational Plan for The Prostate Cancer Portfolio – Casodex & Zoladex | Late disclosure Relevance as to Casodex | AstraZeneca |
| 982N | AZ0432467-80 | 4/29/02 | Email from Connie McDonough to Kathryn Jones re: Zoladex 2003 Product Strategic Plan | Late disclosure | AstraZeneca |
| 982O | AZ0008130-50 | 1992-94 | Zoladex Medical/Marketing Operational Plan | Late disclosure | AstraZeneca |
| 982P | AZ0008087-91 | 1994 | Zoladex Medical Marketing Operational Plan | Late disclosure | AstraZeneca |
| 982Q | AZ0008069-86 | 1995 | Pharma Deliverables Report – Zoladex Medical Marketing Operational Plan | Late disclosure | AstraZeneca |
| 982R | AZ0024003-10 | 8/16/95 | Zoladex 3.6mg and 10.8mg Prostate Cancer 1996 Operational Plan – Draft #1 | Late disclosure | AstraZeneca |
| 982S | AZ0389025 | | Call Notes from AZ Sales Representative Charels Dadonna | Late disclosure | AstraZeneca |
| 982T | AZ0385646 | 6/25/00 | Call Notes from Dana Nevil, AZ Sales Representative | Late disclosure | AstraZeneca |
| 982U | AZ0069688-701 | 5/1/96 | Zeneca Pharmaceuticals Agreement – Urology Groups | Late disclosure | AstraZeneca |
| 982V | PXL00955-67 | 1/13/99 | Letter from Fred Roberts to Marci Calli attaching an 1998-99 executed contract between Parexel & AstraZeneca | Late disclosure | AstraZeneca |

| Ex. | Prod. No. | Date | Description | Objections | Defendant(s) Objecting |
|------------|------------------|-------------|--|-------------------|-----------------------------------|
| 982W | PXL00036-49 | | Memorandum to Keith Patterson & Cyndee Davies from Sandy Robinson attaching 1994 partially executed contract between Parexel & AstraZeneca | Late disclosure | AstraZeneca |
| 982X | AZ0036327 | | Letter to Keith Patterson from Sean Coakley | Late disclosure | AstraZeneca |
| 982Y | AZ0096323 | | “An Evening With Ray Painer, M.D.” | Late disclosure | AstraZeneca |

Respectfully submitted,

THE FOLLOWING TRACK 1 DEFENDANTS

By: /s/ Katherine B. Schmeckpeper

Nicholas C. Theodorou (BBO # 496730)
 Michael P. Boudett (BBO# 558757)
 Katherine B. Schmeckpeper (BBO #663200)
 FOLEY HOAG LLP
 155 Seaport Boulevard
 Boston, MA 02110

D. Scott Wise
 Michael Flynn
 Kimberley Harris
 Davis Polk & Wardwell
 450 Lexington Avenue
 New York, NY 10017

Attorneys for AstraZeneca Pharmaceuticals LP

Steven M. Edwards
 Lyndon M. Tretter
 Hogan & Hartson, LLP
 875 Third Avenue, Suite 2600
 New York, NY 10022

Attorneys for the Bristol-Myers Squibb Co. and Oncology Therapeutics Network Corp.

William F. Cavanaugh, Jr.
Andrew D. Schau
Erik Haas
Patterson, Belknap, Webb & Tyler LLP
1133 Avenue of the Americas
New York, NY 10036-6710

Attorneys for the Johnson & Johnson Defendants

John T. Montgomery (BBO #352220)
Steven A. Kaufman (BBO #262230)
Eric P. Christofferson (BBO #654087)
Ropes & Gray LLP
One International Place
Boston, MA 02110

Attorneys for Schering-Plough Corp. and
Warrick Pharmaceuticals Corp.

Dated: October 17, 2006

CERTIFICATE OF SERVICE

I certify that a true and correct copy of the foregoing was delivered on October 17, 2006 to counsel for plaintiffs and to all counsel of record by electronic service pursuant to Paragraph 11 of Case Management Order No. 2, via LexisNexis File & Serve.

By: /s/ Katherine B. Schmeckpeper
Katherine B. Schmeckpeper